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ABSTRACT
NOVEL STRATEGIES TO MODULATE SYNAPTIC COMMUNICATION AND
INVESTIGATE THE ROLE OF HDAC6 IN ALZHEIMER’S DISEASE
MAY 2014
KATHRYNE A. MEDEIROS
B.S., BRIDGEWATER STATE UNIVERSITY
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor James J. Chambers
Neuronal communication is mediated by chemical signaling at the synapse. The
underlying molecular mechanisms of learning and memory are poorly understood. Very
few tools are available to study how memories are formed in the mammalian brain. This
dissertation focuses on developing novel strategies to study neural activity. Here we
develop and use a chemical-genetic approach to enable target-specific photocontrol of
inhibitory synaptic neurotransmission of GABAA receptor subtypes. The tools developed
here selectively photocontrolled GABAA receptor subtypes.

This enabled the

investigation of the functional role these receptor subtypes have in inhibitory synaptic
neurotransmission. This dissertation also focuses on identifying the role of HDAC6 in
Alzheimer’s disease. Increased expression of HDAC6 was identified as an underlying
molecular factor that led to pathological tau accumulation and early changes that
correlate with synaptic dysfunction, hallmarks of Alzheimer’s disease.
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CHAPTER 1
INTRODUCTION

1.1 Neurons
Neurons

are

post-mitotic

polarized

communication via chemical signaling.

cells

in

the

brain

specialized

for

The main morphological characteristics of a

neuron are a cell body with a single axon and multiple dendrites extending from the cell
body (Figure 1.1A).

Axon morphology and function is dependent on microtubules

(Conde and Caceres, 2009).

Dendrites have branched processes of micron-sized

protrusions called dendritic spines (Perez et al., 2009; Penzes et al., 2011; Shirao and
Gonzalez-Billault, 2013; Jaworski et al., 2009). The morphology and function of dendritic
spines is dependent on cytoskeletal actin filaments (Sala and Segal, 2014; Hotulainen
and Hoogenraad, 2010; Dent et al., 2011; Gu and Zheng, 2009). Both microtubules and
actin dynamics are critical for the development of neuronal polarity and synaptic
communication (Conde and Caceres, 2009). The polymerization dynamics of actin and
microtubules play an important role in neuron morphology, communication, and survival.
The axon contains a parallel bundle of microtubules with the plus ends oriented
towards the cell periphery and the minus end oriented towards the cell body (Dixit et al.,
2008; Conde and Caceres, 2009; Shirao and Gonzalez-Billault, 2013). Microtubules are
integral structural components of the cell composed of α and β tubulin heterodimers that
are necessary for cytoskeleton support serving as a track for directional axonal transport
of cargos such as proteins, vesicles, and organelles (Buee et al., 2000; Conde and
Caceres, 2009).

Neuronal survival depends on highly regulated functional axonal

transport of cargos to and from the cell body to distal portions of the cell.
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Figure 1.1. Neuron Morphology
A) Cartoon depiction of a healthy polarized neuron illustrating the main features of a
neuron including axon, soma, presynaptic axon terminal, dendrites, and postsynaptic
dendritic spines.
B) Cartoon depiction of morphological characteristics of postsynaptic dendritic spines.
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The axon transmits chemical signals via neurotransmitter release at the
presynaptic terminal. Dendrites have multiple branched processes of dendritic spines
that receive these chemical signals at a site called the postsynaptic terminal.
Communication between the presynaptic terminal and the postsynaptic terminal form a
specialized site of chemical signaling responsible for neurotransmission as well as
learning and memory and is called the synapse. Trafficking of cargo to presynaptic and
postsynaptic terminals contribute to the development of mature synapses (Niesmann et
al., 2011). Changes in size and shape of the dendritic spine correlate with the strength
of the synaptic connection and the remodeling of the underlying actin cytoskeleton
(Hotulainen and Hoogenraad, 2010). Dendritic spines are highly dynamic structures that
change size and shape at timescales that range from seconds to minutes to hours
(Hering and Sheng, 2001; Kasai et al., 2010). Dendritic spines are often categorized by
morphology into three categories: thin spines, stubby spines, and mushroom spines
(Figure 1.1B) (Hotulainen and Hoogenraad, 2010; Jaworski et al., 2009; Harris and
Kater, 1994; Hering and Sheng, 2001).

These classifications of dendritic spine

morphology are critical for neuronal communication and believed to be snapshots of
underlying synaptic plasticity (Shirao and Gonzalez-Billault, 2013).

1.2 Synaptic Plasticity
The ability of a neuron to modify communication at the synapse in response to
changes at the synapse is referred to as synaptic plasticity. Synaptic plasticity is the
underlying mechanism of learning and memory. This change in synaptic strength is
regulated at the presynaptic terminal by neurotransmitter release and by receptors at the
postsynaptic terminal.

Homeostasis of neuronal communication is maintained by a

balance between strengthening synaptic communication by long-term potentiation (LTP)

3

and reducing the strength of synaptic communication by long-term depression (LTD)
(Figure 1.2).
LTP is an increase in synaptic strength and associated with dendritic spine
enlargement (Kasai et al., 2010; Shepherd and Huganir, 2007; Pontrello et al., 2012;
Collingridge et al., 2004).

Enlargements of dendritic spines and increased receptor

trafficking to the postsynaptic sites are associated with LTP. Changes in the functional
strength of synapses, the size and shape of dendritic spines, as well as the physical
connectivity of neural networks all contribute to LTP (Bingol and Sheng, 2011). LTD is a
decrease in synaptic strength associated with a reduction in the number and size of
dendritic spines (Pontrello et al., 2012; Shepherd and Huganir, 2007). This reduction in
dendritic spine size and number as well as decreased receptor trafficking are associated
with LTD. Altered neuronal communication at the synapse and a decreased number of
postsynaptic receptors correlate with a reduction in synaptic strength and plasticity
(Bingol and Sheng, 2011).

Actin polymerization is involved in LTP and actin

depolymerization is involved in LTD (Matsuzaki et al., 2004; Okamoto et al., 2004; Zhou
et al., 2004).

Synaptic remodeling and cellular homeostasis requires proper protein

turnover that is coordinated by protein synthesis and protein degradation (Bingol and
Sheng, 2011).
Impaired LTP and induced LTD are associated with disease and defects in
learning and memory (Hering and Sheng, 2001; Keifer and Zheng, 2010; Shepherd and
Huganir, 2007). Abnormal synaptic communication resulting from changes in dendritic
spine density and shape has been observed in a number of neurological disorders
(Penzes et al., 2011). Defects in protein degradation lead to the accumulation of toxic
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Figure 1.2. Synaptic Plasticity
Cartoon illustration of mechanisms underlying synaptic plasticity. During LTP there is an
increase in synaptic strength and receptors at the synapse where as during LTD there is
a decrease in synaptic strength and receptors at the synapse. Excitatory
neurotransmission at the synapse is regulated by glutamate neurotransmitter release
and two main types of glutamate-gated ion channels: AMPA and NMDA. Inhibitory
neurotransmission at the synapse is regulated by γ-aminobutyric acid (GABA)
neurotransmitter release and ionotropic GABAA receptors.
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protein aggregates and are associated with neurological diseases. Reduced protein
degradation is the result of defective protein clearance.

Defects in the ubiquitin

proteasome system (UPS), lysosomes, and autophagy have been associated with
defective protein clearance and neurological disease (Bingol and Sheng, 2011). Protein
aggregation, accumulation, and deposition are hallmarks of neurodegenerative diseases
and are believed to be the result of impaired protein degradation pathways. Impaired
synaptic plasticity is the result of degeneration of axons and dendritic spines leading to
loss of synapses.

1.3 Excitatory and Inhibitory Neurotransmission
Communication at the synapse is mediated by neurotransmitter release from the
presynaptic terminal and receptor activation at the postsynaptic terminal.

Excitatory

neurotransmission at the synapse is regulated by glutamate neurotransmitter release
and two main types of glutamate-gated ion channels: α-amino-3-hydroxy-5-methyl-4isoxazolepropionic acid (AMPA) receptors and N-methyl-D-aspartate (NMDA) receptors
(Collingridge et al., 2004; Keifer and Zheng, 2010; Pinheiro and Mulle, 2008; Rao and
Finkbeiner, 2007).

AMPA receptors are composed of combinations of four subunits

(GluR1, GluR2, GluR3, GluR4) (Rao and Finkbeiner, 2007; Shepherd and Huganir,
2007). NMDA receptors are heterotetramers composed of combinations of NR1 subunit,
NR2 subunits (NR2A, NR2B, NR2C, NR2D), and NR3 subunits (NR3A, NR3B) (Paoletti
et al., 2013). An important scaffolding protein, postsynaptic density protein 95 (PSD-95)
plays a pivotal role in LTP and LTD (Bhattacharyya et al., 2009; Chen et al., 2011).
PSD-95 plays a functional role in maintaining molecular organization of excitatory
dendritic spines.

PSD-95 is the most-abundant scaffolding protein in postsynaptic

densities, and is one of the most stable proteins in dendritic spines (Chen et al., 2011;
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Kasai et al., 2010).

Inhibitory neurotransmission at the synapse is regulated by γ-

aminobutyric acid (GABA) neurotransmitter release and ionotropic GABAA receptors
(D'Hulst et al., 2009). GABAA receptors are heteropentamers containing the common
stoichiometry of two subunits of α and two β and an additional subunit of γ or δ (Belelli
and Lambert, 2005). Variation of subunit composition of receptors allows for differential
expression patterns, localization (extrasynaptic vs. synaptic), pharmacology and
function.

The role that subunit composition, differential expression patterns,

extrasynaptic and synaptic localization plays in synaptic communication, function and
dysfunction in neurological diseases has been elusive.

1.4 Controlling Synaptic Neurotransmission
Mammalian cells have ion channels that are activated by ligand binding, voltage,
and temperature but they are not activated by light (Banghart et al., 2004). To control
neural circuits, we can engineer ion channels to be activated or inhibited by light.
Engineering ion-channels to respond to light enables exploration and manipulation of
synaptic neurotransmission. Light is a non-invasive method that enables spatial and
temporal resolution to control neural activity (Boyden et al., 2005; Fortin et al., 2008;
Kramer et al., 2005; Kramer et al., 2009; Thompson et al., 2005).

Advances in

microscopy, optical physics and laser instrumentation allows for a beam of light of a
certain wavelength to be focused on a subcellular region of a cell, on a single cell, or
projected diffusely to regulate a network of cells thus activating or inhibiting ion channels
enabling photocontrol of synaptic neurotransmission that regulates synaptic plasticity
and behavior using light (Fortin et al., 2008; Kramer et al., 2005; Thompson et al., 2005).
Optical methods for controlling synaptic neurotransmission using light include:
caged neurotransmitters, natural photosensitive proteins, and synthetic small molecule
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photoswitches (Chambers and Kramer, 2008; Kramer et al., 2005; Thompson et al.,
2005). These optical light sensitive tools offer precise, non-invasive control of neural
activity. Caged neurotransmitters have a photolabile protecting group that renders them
biologically inactive until the protecting group is removed or ‘uncaged’ upon exposure to
light releasing the neurotransmitter (Ellis-Davies, 2007; Fortin et al., 2008; Kramer et al.,
2009; Thompson et al., 2005). Caged neurotransmitters have several caveats: lightscattering limits the precision of uncaging, the uncaging of neurotransmitter is
irreversible, prolonged uncaging can lead to receptor desensitization and local depletion
of the caged neurotransmitter can limit long-term experiments (Fortin et al., 2008;
Kramer et al., 2009). Advances in molecular biology led to gene delivery of the natural
photosensitive protein Channelrhodopsin-2 (ChR2), a light-gated cation channel that
contains the photoisomerizable molecule retinal to neuronal subtypes (Boyden et al.,
2005; Zhang et al., 2006). Exposure to light triggers retinal isomerization leading to a
conformational change in the photosensitive protein, which opens the channel thus
enabling photocontrol of neurons. A caveat to natural photosensitive proteins is that the
gene encoding the photosensitive protein needs to be delivered to the neurons of
interest and the protein needs to be expressed and trafficked to the plasma membrane.
Alternatively, photocontrol of neurons can be achieved through synthetic chemistry and
the use of small molecule photoswitches.
Small molecule photoswitches have been used to convert ion channels to lightsensitive ion channels. Small molecule photoswitches are photoisomerizable molecules
in which the conformation of the molecule changes in response to specific wavelengths
of light. Azobenzenes as a small molecule photoswitch that have been commonly used
to develop synthetically-photosensitive ion channels. Azobenezenes are often the small
molecule photoswitch of choice because of their biological suitability, low phototoxicity,
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ease of synthesis, and photochemical stability (Kramer et al., 2009).

Azobenzenes

photoswitch from an extended trans isomer conformation in response to illumination with
visible light >460 nm and upon illumination with ultraviolet (UV) light at 380 nm convert
to a cis bent isomer conformation approximately 7Å shorter than the trans isomer
conformation (Figure 1.3) (Banghart et al., 2006; Feliciano et al., 2010). A ligand can
then be coupled to the small molecule photoswitch to target the photoswitchable ligand
to a receptor of interest by affinity labeling. In order to prevent the limitations of using a
freely diffusible light-sensitive photoswitchable ligand often a molecule that can
covalently bind the photoswitchable ligand to the receptor of interest is employed.
Maleimide molecules are commonly used to covalently attach photoswitchable ligands to
receptors by cysteine-reactivity to residues on the surface of the target protein.
Specificity can be achieved by engineering a cysteine to a specific location on the
receptor of interest rather than relying on endogenous cysteines. Genetic engineering of
a cysteine to the appropriate location for target photoswitch tethering prevents diffusion
of photo-tethered ligand and off target effects.

Attachment of the small molecule

photoswitch to the ion channel of interest enables photocontrol of receptor activity.
By employing a photoswitchable tethered ligand (PTL) to photocontrol ion
channels the activity of a neuron can be modulated by light without diffusion of the PTL
thus increasing the local concentration of the ligand near the target protein. This “drugs”
activity can be turned on and off using specific wavelengths of light to control chemical
signaling of receptors involved in learning and memory at synapses thus creating a lightgated ion channel that can be reversibly photocontrolled in response to irradiation with
ultraviolet or visible light by altering the location of the ligand in relation to the ligand
binding site (Figure 1.4). This PTL strategy has been used to photocontrol the activity of

9

Figure 1.3. Azobenzene Photoswitch
Illustration showing azobenzene isoform configuration to extended trans isomer in
response to irradiation with visible light (>460 nm) and to bent cis isomer in response to
irradiation with ultraviolet light (360-380 nm). Figure adapted from (Banghart et al.,
2006).
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ontrol of neuronal activity. Three categories of tools are illustrated: caged molecules (left), natural photosensitive proteins
le photoswitches (right). Specific examples are shown below in the green boxes. Abbreviations: DMNB-glu, 4,5-dimethoxy4]; MNI-glu, 4-methoxy-7-nitroindolinyl-caged glutamate [6!!]; ChR2 (channelrhodopsin-2), a cation channel from
tii [22!!]; VChR1 (channelrodhopsin-1), a cation channel from Volvox carteri [38]; NpHR (halorhodopsin), a chloride
monas pharaonis [29!!,30]; PAC, a photoactivatable adenylyl cyclase isolated from Euglena gracilis [39]; Opto-XRs,
or rhodopsin/b2-adrenergic receptor chimeras [42!]; LOV, the phototropin-1 light oxygen voltage domain from Avena sativa
photoisomerizable azobenzene-regulated K+ channel; D-SPARK [46!!], a depolarizing SPARK channel [47]; LiGluR, a lightFigure 1.4. Photocontrol of dibromide
Ion Channels
ptor [48!!]; Bis-Q, 3,30 -bis[a-(trimethylammonium)methyl]azobenzene
[44]; QBr, 3-(alpha-bromomethyl)-30 -[alphayl]azobenzene bromide [45]; AAQ, acryl–azobenzene–quaternary ammonium [52!!]; Glu-Azo, azobenzene–glutamate [54].

Cartoon illustration of the photocontrol of ion channels. Tethered small molecule
photoswitches enable remote photocontrol of neuron ion channels using specific
light.
Shown
photocontrol
of neuronal firing of synthetic
ed nucleotides, and evenwavelengths
caged pep- ofglutamate
has
a veryhere
low rate
+ of spontaneous glutamate
photoisomerizable
azobenzene-regulated
K
(SPARK)
channels.
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with
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spontaneous
action
potential
firing
occurs,
and
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ged neurotransmitter agonists were
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with
ultraviolet
light)
potentials
are silenced. Figure adapted from (Kramer et al.,
tives of carbamoylcholine, an activaeffectaction
on neuronal
function.
2005).
e receptors that was released in

ht [1,2]. These molecules enabled a
st concentration in response to light,
understanding of the kinetics of
or activation. But it was the develtamate [3] that had a major impact on
and Katz were the first to use a laser
utamate in an intact brain slice [4].
ion of presynaptic neurons revealed
onnections to visual cortical neurons
elopment, a finding that would have
ain without local glutamate uncaging.

ever, light scattering limits the spatial
caging. This problem motivated the
ed molecules that could be photoillumination, which can pinpoint the
ansmitter to individual neurons and
dritic spines. MNI-caged glutamate
ndolinyl-caged L-glutamate) has a
n cross-section, and because of this,
opular form of caged glutamate (for
dding to its usefulness, MNI-caged

Two-photon uncaging of MNI-glutamate can trigger
responses that simulate the kinetics and magnitude of
individual synaptic events on single dendritic spines [6!!].
Fortunately, abundant and highly active glutamate transporters rapidly remove the liberated glutamate, minimizing spillover onto neighboring spines. Uncaging at single
spines is beneficial for several reasons. It allows direct
comparison of spine geometry and postsynaptic responsiveness. It allows precise measurement of spatial summation across neighboring spines. It removes any
ambiguity in attributing plastic changes in synaptic function to the presynaptic versus the postsynaptic cell.
Highly localized and rapid uncaging of glutamate requires
very bright light and a high concentration of caged
compound (mM range). These requirements present
potential problems of phototoxicity and off-target effects
on other types of receptors. The development of new
types of caged glutamate with
11 an even more favorable
two-photon cross-section may help alleviate these problems [7,8]. At the same time, investigators are developing forms of caged glutamate that can be uncaged by

glutamate receptors and shaker K+ channels (Banghart et al., 2006; Chambers et al.,
2006; Volgraf et al., 2006).

The PTL approach allows reversible photocontrol of

neuronal receptors and can be applied to a variety of receptors using both genetic and
chemical engineering. This technology allows for investigation of the role receptor
subtypes play in synaptic communication and their function.

1.5 Alzheimer’s disease

Alzheimer’s disease (AD) is a chronic, progressive, neurodegenerative disease
with no cure. AD is the most common form of dementia and the 6th leading cause of
death in the United States (Thies et al., 2013). According to the 2010 US Census and
the Chicago Health and Aging Project (CHAP) the estimated prevalence of AD is 11% of
individuals older than 65 years of age have AD, and approximately 32% of people aged
85 and older have AD (Thies et al., 2013). Memory impairment is the earliest symptom
of AD (Nestler et al., 2009; Thies et al., 2013). As disease progression occurs, cognitive
impairment increases and eventually patients exhibit complete loss of independence
(Nestler et al., 2009).

It is estimated that by 2040, there will be 80 million people

worldwide with AD (Nestler et al., 2009).

The underlying cause or causes and the

precise sequence of changes in the human brain that trigger the development of
sporadic AD are unknown (Thies et al., 2013).

Sporadic AD is believed to be a

multifactoral, slow progressing disease in which the sequence of changes in the brain,
and the accumulation of pathological proteins, leads to neuronal dysfunction that
ultimately leads to neuronal death correlating with defects in memory and cognition, the
symptoms of AD. These underlying changes are believed to occur between 10 and 20
years before any memory or cognitive impairment occurs (Gravitz, 2011; Thies et al.,
2013).
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In 1907, Alois Alzheimer first discovered and characterized the two pathological
hallmarks of AD: neurofibrillary tangles (NFTs) and amyloid-beta (Aβ) plaques from the
brain of a diseased patient (Spires-Jones et al., 2009).

NFTs are intracellular

aggregates of insoluble hyperphosphorylated tau whereas Aβ plaques are extracellular
aggregates of Aβ produced from the proteolytic cleavage of the amyloid-β precursor
protein (APP) by β and γ secretases (Figure 1.5) (Andorfer et al., 2003; Bordji et al.,
2010; Mazanetz and Fischer, 2007). The accumulation of both of these aggregates
correlate with loss of synapses and neuronal death, which leads to memory impairment,
cognitive decline, and disease progression. Intracellular NFTs are believed to impair
cellular transport of nutrients, cargos, and neurotransmitters where as extracellular Aβ
plaques are believed to interfere with synaptic communication (Thies et al., 2013).
Additionally, it has been shown that neuron death leads to brain atrophy, reducing the
size of an AD brain compared to a normal healthy brain (Santacruz et al., 2005).
Significant reduction in postsynaptic density protein 95 (PSD-95), AMPARs, and
NMDARs are found in the post-mortem brains of AD patients (Keifer and Zheng, 2010;
Proctor et al., 2011). This reduction in PSD-95, AMPARs, and NMDARs are associated
with LTD and deficits in LTP. The reduction of postsynaptic scaffolding protein, PSD-95,
is believed to contribute to AMPA receptor dependent LTP deficits in AD (Proctor et al.,
2011).

Loss of synapses and dendritic spines are a common pathology in human

postmortem brains (Tackenberg et al., 2009).

Additionally, synapse loss precedes

neuron death indicating disruption of neuronal communication at the synapse is an early
event in disease progression (Selkoe, 2002). The extent of disease progression and
cognitive impairment in AD patients correlates with degree of synaptic loss (Terry et al.,
1991). Synaptic dysfunction, LTP deficits and memory impairment have been observed
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Figure 1.5. Pathological Hallmarks of Alzheimer's Disease
Cartoon illustration of degenerating neuron in Alzheimer’s disease with intracellular
neurofibrillary tangles (NFTs) accumulating in the soma and extracellular amyloid-beta
(Aβ) plaques. The presynaptic axon terminal shows shrinkage representative of
synaptic dysfunction in the degenerating neuron.
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in AD mouse models before the accumulation of Aβ plaques and NFTs indicating
synaptic dysfunction underlies the initial development of the disease (Oddo et al., 2003).
Impaired synaptic plasticity is believed to be one of the earliest and prominent
pathologies in an AD brain mediating cognitive defects and memory impairment (Penzes
et al., 2011). Changes in postsynaptic strength contribute to synaptic dysfunction in AD.
Decreased synaptic communication and synaptic dysfunction precedes neuronal death.
Abnormal accumulation of protein aggregates composed of Aβ plaques and
NFTs in AD is believed to contribute to synaptic dysfunction and neuron death in late
stages of AD progression. Impaired synaptic plasticity and spine loss is associated with
accumulation of Aβ plaques and NFTs (Tackenberg et al., 2009). Defects in synaptic
plasticity, impaired LTP and induced LTD have been associated with Aβ plaque and NFT
accumulation (Ittner and Gotz, 2011; Malinow, 2012).

Dysfunction of protein

degradation clearance mechanisms is believed to contribute to AD progression.
Ubiquitin-proteasome system (UPS) dysfunction, impaired lysosomal degradation, and
impaired autophagy have been found in AD (Keller et al., 2000; Ling et al., 2009; Min et
al., 2010; Wolfe et al., 2013). Since the discovery of these two pathological hallmarks,
research has focused on trying to prevent the accumulation of aggregated Aβ plaques
and NFTs in an effort to prevent the progression of AD (Gravitz, 2011). Each hallmark
has been extensively studied individually; the focus has been on their separate modes of
toxicity (Ittner and Gotz, 2011). Recent evidence has suggested synergistic roles in
mediating AD progression and possible interactions between Aβ plaques and NFTs
(Ittner and Gotz, 2011).

Additionally it is believed that both Aβ plaques and NFTs

directly contribute to defects in synaptic plasticity by impairing LTP and LTD.
NFTs are aggregates of hyperphosphorylated tau that are mistargeted to both
the soma and dendritic spines (somatodendritic compartment). NFTs are implicated in
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mediating Aβ toxicity and synaptic dysfunction in AD. Hyperphosphorylated tau in the
somatodendritic compartment modulates the activity of the src-tyrosine kinase, Fyn, via
the amino-terminal projection domain of tau (Ittner and Gotz, 2011; Hoover et al., 2010;
Ballatore et al., 2007; Roberson et al., 2011). This Fyn-tau interaction is believed to
target Fyn to dendritic spines (Ittner and Gotz, 2011). Fyn phosphorylates excitatory
ionotropic glutamate N-methyl-D-aspartate receptors (NMDAR) subunit 2B (NR2B)
facilitating interaction with postsynaptic density protein 95 (PSD-95) in the postsynaptic
compartment (Ittner and Gotz, 2011).

Phosphorylation of NMDAR can result in

excitotoxic downstream signaling (Ittner et al., 2010). Hyperphosphorylated tau exhibits
increased affinity for Fyn, resulting in increased localization of postsynaptic Fyn,
phosphorylated NMDARs and potentially results in excitotoxic signaling (Bhaskar et al.,
2005; Ittner and Gotz, 2011). This excitotoxic downstream signaling of NMDARs results
in neurotoxicity, Ca2+ dysregulation, synapse loss, and increased Aβ toxicity in AD
(Alberdi et al., 2010; Hoover et al., 2010; Ittner and Gotz, 2011; Malinow, 2012;
Roberson et al., 2011).
Multiple studies have shown that Aβ plaques alter synapse formation, reduces
surface expression of NMDAR and AMPARs, promotes NMDAR endocytosis, loss of
dendritic spines, and induces Ca2+ dysregulation and neuronal death by activation of
NMDARs and AMPARs (Alberdi et al., 2010; Hsieh et al., 2006; Liu et al., 2010; Penzes
et al., 2011; Snyder et al., 2005). NMDARs at the synapse are neuroprotective whereas
extrasynaptic NMDAR are neurotoxic (Hardingham and Bading, 2010).

Compelling

recent evidence from AD mouse models have implicated that in the absence of tau the
postsynaptic targeting of Fyn is disrupted, decreasing both NMDAR-mediated
excitotoxicity and Aβ postsynaptic toxicity (Ittner et al., 2010; Roberson et al., 2011).
Additionally, hyperphosphorylated aggregated tau has increased association with Fyn
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and this interaction has been implicated in mediating Aβ toxicity and synaptic
dysfunction in AD (Bhaskar et al., 2005; Ittner et al., 2010; Roberson et al., 2011).
Clearly, these synergistic roles of Aβ plaques and NFTs enhance late stage AD
progression. The degree of accumulation of both of these aggregates is an indicator of
the level of synaptic dysfunction, memory impairment, cognitive decline, and disease
progression. Targeting the accumulation of Aβ plaques and NFTs remains controversial.
Many researchers disagree on which pathological hallmark is key to preventing AD
progression and focus on targeting proteins involved in the accumulation Aβ plaques
and NFTs. Other researchers believe Aβ plaques and NFTs are not the right target
because they appear after synaptic dysfunction has occurred.

AD is a complex

multifactoral disease of dying neurons. The earliest known pathology contributing to AD
progression is synaptic dysfunction (Oddo et al., 2003; Penzes et al., 2011). Some
researchers have recently shifted to identifying and targeting underlying molecular
factors leading to synaptic dysfunction, and ultimately Aβ plaques and NFTs
accumulation.
A unique class IIb histone deacetylase (HDAC) with cytoplasmic localization,
HDAC6 (Li et al., 2013; Xu et al., 2011), has emerged as a potential key player in a
number of neurodegenerative diseases such as Alzheimer’s disease, Huntington’s
disease, Parkinson’s disease, and Amyotrophic lateral sclerosis (ALS). HDAC6 may be
an underlying factor leading to synaptic dysfunction in these neurodegenerative
diseases. Unlike other HDACs, HDAC6 has two catalytic deacetylase domains, a Ser
Glu-peptide repeat domain (SE14), which acts as a cytoplasmic retention signal, and a
BUZ domain that binds polyubiquitinated proteins (Ding et al., 2008; Li et al., 2013).
HDAC6 is a versatile multifunctional enzyme responsible for deacetylating key proteins
involved in protein degradation pathways, cellular stress, and cytoskeletal dynamics
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(d'Ydewalle et al., 2012; Li et al., 2013; Parmigiani et al., 2008; Zhang et al., 2013). The
role of HDAC6 in neurodegenerative disease is controversial as it is unclear if HDAC6
functions as neuroprotective or neurotoxic.
HDAC6 deacetylates two important cytoskeletal proteins, α-tubulin subunits of
microtubules and cortactin, a filamentous actin binding partner (Hubbert et al., 2002;
Zhang et al., 2007). Deacetylation of α-tubulin renders microtubules less stable and
leads to depolymerization (Hubbert et al., 2002; Matsuyama et al., 2002). Deacetylation
of cortactin inhibits binding to filamentous actin leading to actin depolymerization,
impairing cell motility (Kaluza et al., 2011; Zhang et al., 2007).

HDAC6 alters

cytoskeletal dynamics by influencing depolymerization of key proteins involved in
synaptic remodeling.
HDAC6 is an integral protein with diverse functions in mediating and coordinating
cellular response to the cytotoxic accumulation of misfolded and aggregated proteins by
interacting with polyubiquitinated proteins when UPS degradation is impaired by
activating both autophagy and heat-shock proteins (Kalveram et al., 2008; Matthias et
al., 2008; Pandey et al., 2007). Thus, HDAC6 is an important protein for coordinating
the sequestration of protein aggregates and their clearance.

Another cellular stress

response that HDAC6 has is in redox regulation. Cellular stress leading to accumulation
of reactive oxygen species can be detrimental to cell survival and are common in
neurodegenerative diseases.

HDAC6 deacetylates two redox regulatory antioxidant

enzymes peroxiredoxin I (PRXI) and II (PRXII), which when deacetylated function to
reduce H2O2 (Parmigiani et al., 2008).
Evidence from post-mortem AD human brains, AD animal models, and AD
studies suggest that HDAC6 may be an underlying molecular factor that becomes
neurotoxic when upregulated and thus contributes to AD pathology and progression. In
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fact, immunoblots from post-mortem human AD brains have shown that HDAC6 protein
levels are increased 52% in the cortex and 91% in the hippocampus compared to agematched control brains (Ding et al., 2008). HDAC6 is known to mediate and coordinate
cellular response to the cytotoxic accumulation of misfolded and aggregated proteins
and in AD misfolded aggregated proteins accumulate yet UPS dysfunction, impaired
lysosomal degradation, and impaired autophagy have been shown in AD (Keller et al.,
2000; Ling et al., 2009; Min et al., 2010; Wolfe et al., 2013).

A number of recent

publications have illustrated that reduction or loss of HDAC6 reduces cognitive deficits in
a mouse model for AD, alleviates abnormal tau accumulation, and rescues
phosphorylated tau-mediated microtubule instability (Cook et al., 2012; Govindarajan et
al., 2013; Xiong et al., 2013). This data suggest that increased expression of HDAC6 is
neurotoxic in AD and that targeting HDAC6 may be a potential strategy for preventing
the progression of AD.

The question remains whether HDAC6 is an underlying

molecular factor leading to synaptic dysfunction, and ultimately NFTs and Aβ plaques
accumulation.
HDAC6 has previously been shown to interact with a key protein phosphatase,
protein phosphatase 1 (PP1), via HDAC6’s second catalytic domain (Brush et al., 2004).
PP1 is an important phosphatase responsible for removing phosphate groups from
proteins, regulating their function.

One protein regulated by PP1 is tau.

Tau is a

microtubule-associated protein (MAP), primarily expressed in neurons that promote
microtubule assembly and stabilization (Iqbal et al., 2005). PP1 has been shown to
interact and dephosphorylate tau, increasing the affinity of tau for microtubules and
stabilizing them (Liao et al., 1998). Dysregulated tau homeostasis results in increased
tau phosphorylation and subsequently abnormally hyperphosphorylated tau with reduced
affinity for microtubules and this form of hyperphosphorylated tau forms NFT in AD
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(Andorfer et al., 2003; Spires-Jones et al., 2009).

Interestingly, a domain-selective

small-molecule enzyme inhibitor tubacin, targets the second catalytic domain of HDAC6
preventing HDAC6 from deacetylating α-tubulin (Haggarty et al., 2003). In vitro inhibition
of HDAC6 by tubacin was shown to attenuate tau phosphorylation, however, it is unclear
if tubacin disrupted an HDAC6-PP1 interaction enabling PP1 to dephosphorylate tau
(Ding et al., 2008). Additionally, shRNA-mediated knockdowns of HDAC6 were shown
to attenuate tau phosphorylation suggesting HDAC6 regulates PP1 activity (Ding et al.,
2008). These data suggest that overexpression of HDAC6 alters PP1 enzymatic activity
thus creating an imbalance of kinase and phosphatase activity that leads to the aberrant
hyperphosphorylation of tau. A proposed model of HDAC6 mediated AD pathology and
synaptic dysfunction is shown in Figure 1.6.
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Figure 1.6. Model of HDAC6 Mediated Alzheimer's Disease Pathology
Cartoon illustration of HDAC6 mediated AD pathology and synaptic dysfunction in
degenerating neuron. An increase in HDAC6 protein levels leads to decreased PP1
activity. The changes in HDAC6 protein levels and PP1 activity lead to an increase in
pathological hyperphosphorylated tau assembling into intracellular neurofibrillary tangles
(NFTs) which accumulates in the soma of the degenerating neuron along with
extracellular accumulation of amyloid-beta (Aβ) plaques. These changes ultimately lead
to synaptic dysfunction in the degenerating neuron.
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1.6 Motivation
The overall goals of this thesis are to develop novel strategies to understand
underlying mechanisms of synaptic communication, and learning and memory.

The

mammalian brain is a complex system with very few tools to study how memories are
formed, the function of receptor subtypes, and changes that lead to disease.

By

developing novel strategies to study neural activity using pharmacology tools and
genetics, we can perturb the system and discover the role of receptor subtypes in
controlling neural activity and the role of specific proteins in disease progression. By
developing novel photoswitchable tethered ligands photocontrol of specific ion channels
can be achieved, allowing the discovery of the role those receptors have in regulating
learning and memory at the synapse.
Efforts by scientists and pharmaceutical companies to target AD pathology and
progression late in the disease have been unsuccessful in preventing disease
progression in humans. Early changes that lead to AD pathology and the discovery of
underlying molecular factors leading to synaptic dysfunction and AD progression have
been elusive. Most of what is known about AD progression and pathology comes from
post-mortem adult late-stage AD brains and animal models developed to investigate
plaque and tangle modes of toxicity, disease progression and memory impairment and
cognitive decline. Both models are only snapshots of the disease pathology. The goal
here is to identify key changes that lead to the pathological hallmarks of AD and early
changes that correlate with synaptic dysfunction by developing a neuron cell culture
model system.
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CHAPTER 2

PHOTOCONTROL OF GABAA RECEPTORS
The work presented in this chapter was an interdisciplinary collaboration project between
members of James J. Chambers laboratory at UMASS Amherst, which included Devaiah
Vytla and members of Richard H. Kramer’s laboratory at University of California
Berkeley, which included Wan-Chen Lin, Christopher M. Davenport, Alexandre Mourot,
and Caleb M. Smith. Parts of this chapter are from several manuscripts in preparation or
under current review.

2.1 Introduction
Controlling synaptic neurotransmission with a phototethered ligand (PTL) has
been utilized to photosensitize glutamate channels, K+ channels, and nicotinic
acetylcholine receptors (Banghart et al., 2004; Lester et al., 1980; Volgraf et al., 2006).
The major inhibitory neurotransmission in the brain is controlled by activation of the
GABA receptor by GABA neurotransmitter. The GABA receptor is an untouched target
for a PTL. Ionotropic GABAA receptors are important drug targets in the treatment of
anxiety disorders, sleep disorders, epilepsy and many drugs of abuse, including alcohol,
barbiturates, and benzodiazepines (Jones-Davis and Macdonald, 2003; Atack, 2005;
Mohler, 2006; Korpi et al., 2002; Rudolph and Knoflach, 2011; Smith and Rudolph,
2012). Nineteen genes encoding GABAA receptor subunits have been identified: α1-6,
β1-3, γ1-3, δ, ε, θ, π, and ρ1-3 (Barnard et al., 1998; Olsen and Sieghart, 2008). Subunit
composition of GABAA receptor subtypes determines subcellular localization, expression
patterns, function and pharmacology (Olsen and Sieghart, 2008). The most common
subunit composition for GABAA receptors are two subunits of α and two β and an
additional subunit of γ or δ (Belelli and Lambert, 2005). The α-subunit is important for
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receptor localization and channel gating kinetics, and with the β-subunit forms the
GABA-binding site (Mohler, 2006; Rudolph and Knoflach, 2011).

GABAA receptors

containing the α1-subunit are the most common α-isoform in the brain (Olsen and
Sieghart, 2008). The function of two α-isoforms, α1 and α5 subunits, were of particular
interests to us due to their distinct expression patterns in the hippocampus and
pharmacology.

GABAA receptors containing α1-subunits are believed to detect

presynaptically released GABA and mediate transient “phasic” inhibition, where as
GABAA receptors containing α5-subunits are believed to mediate persistent “tonic”
inhibition (Farrant and Nusser, 2005).
Identifying

the

physiological

function

of

receptor

subtypes

in

synaptic

neurotransmission has been elusive due to the paucity of current pharmacological tools
that target specific subtypes and inability to prevent compensatory changes in gene
expression of other isoforms or related proteins in subtype specific gene-knockout
animals (Kralic et al., 2002; Mohler, 2006; Ortinski et al., 2006; Rudolph and Mohler,
2004; Rudolph and Knoflach, 2011). To overcome these obstacles in discovering the
function of GABAA receptor subtypes in synaptic neurotransmission, we developed a
series of photochemical tools for precise and selective manipulation of specific subtypes
of GABAA receptors.

We designed a chemical-genetic approach to enable target-

specific photocontrol of neuronal inhibition.

We engineered light-regulated GABAA

receptors (LiGABAAR) by employing a PTL strategy for creating light-sensitive α1- and
α5-GABAA receptors.
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2.2 Results
2.2.1

PTL design and photoisomerization of MAM-6
The design of a PTL that targeted GABAA receptor was based on previous

GABAAR probes in which the amino group of a potent GABAA receptor agonist muscimol
was linked to biotin or a fluorophore (Vu et al., 2005). The PTL design contained an
azobenzene photoswitch, which allowed photoisomerization from a trans confirmation
upon irradiation with 500 nm to cis conformation upon irradiation with 380 nm. The
azobenzene photoswitch enabled the conformation of the PTL to change from an
extended trans conformation or retracted cis conformation. Additionally, our PTL design
contains a maleimide group for covalent attachment to genetically engineered cysteine
mutant GABAA receptors. The PTL was named MAM-6 for malemide, azobenzene, and
muscimol linked by a 6-carbon spacer.

This spacer enables muscimol to enter the

GABA-binding pocket. An illustration of the photoisomerization of MAM-6 is shown in
Figure 2.1.
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Figure 2.1. Photoisomerization of MAM-6
Scheme depicting the photoisomerization of MAM-6.
The PTL reversibly
photoisomerizes between elongated trans confirmation upon irradiation with 500 nm
visible light (green) and retracted cis confirmation upon irradiation with 380 nm ultraviolet
light (violet).
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2.2.2

Attachment sites and photoregulation of MAM-6 in α1- and α5-subunit
Potential PTL attachment sites for optimal photoregulation were screened using

the α1-containing GABAA receptor, the most common isoform in the brain. We focused
on a region of the α1 subunit that is close to the GABA-binding pocket, a region between
the α- and β-subunits. Residues facing towards the GABA-binding site were chosen as
PTL attachment sites, residues in yellow were cysteine substituted to make a library of
single-cysteine mutant α1-subunits (Figure 2.2A). Initial testing of the activity of the PTL
was done in an exogenous system where cysteine mutant receptors of interest were coexpressed with wild-type β2-subunit to form functional receptors in Xenopus oocytes.
Muscimol is an agonist of GABAA receptors, yet we found mutant receptors tethered with
MAM-6 were not activated by irradiation with either 380 nm or 500 nm light but were
inhibited (Figure 2.2B). The amplitude of the GABA response decreased under 500 nm
visible light conditions when MAM-6 was in an extended trans conformation and the
current increased when MAM-6 was in a retracted cis conformation under 380 nm
ultraviolet light conditions (Figure 2.2B).

Thus, tethered MAM-6 functioned as an

antagonist under 500 nm visible light conditions.
Next, we made a library of single-cysteine mutant α5-subunits that were
homologous to screened residues of α1-subunits facing towards the GABA-binding site
(Figure 2.2A, Figure 2.2C). We screened for photoregulation to identify the optimal PTL
attachment site in α1- and α5 cysteine mutant receptors. Tethered MAM-6 enabled
photoregulation of both α1- and α5-cysteine mutant receptors (Figure 2.2D) as the
photoregulation index, which is a ratio of GABA-elicited currents in 380 nm vs. 500 nm
(I380/I500). The identified PTL attachment sites that substantially photoregulated GABAelicited current were (α1: S68C, T121C, T125C and α5: S72C).
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Figure 2.2. PTL Attachment Sites and Photoregulation of Engineered α1- and α5
Receptors
A) Homology model of α1β2 subunits showing MAM-6 attachment sites with cysteine
mutated residues in yellow and the GABA binding site with docked muscimol in red.
B) Representative traces from Xenopus oocytes expressing α1(S68C)β2 treated with
MAM-6 showing reversible photoregulation of GABA-elicited current.
C) Sequence alignment with residues chosen for cysteine substitution mutation sites
shown in red for α1 and α5. Residues homologous to tested α1 cysteine-mutants were
chosen as sites for cysteine substitution in α5.
D) Photoregulation after MAM-6 treatment of α1 or α5 mutant receptors expressed in
Xenopus oocytes. Each mutant was co-expressed with wild-type β2 subunit to form the
Supplemental Figure 3. Photosensitization of !5-containing GABAA receptors.
GABA-binding site. Cysteine-mutated residues for α1 or α5 mutant receptors indicated
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2.2.3

Trans MAM-6 inhibits LiGABAAR after PTL treatment
Next, we determined if binding of the PTL altered receptor sensitivity to GABA-

elicited current. Whole-cell patch clamp electrophysiology of GABA-elicited current from
Xenopus oocytes expressing α1(T125C)β2 showed that GABA responses before and
after PTL attachment are similar to GABA responses in the retracted cis conformation
whereas in the extended trans conformation GABA responses are reduced after PTL
attachment (Figure 2.3). The GABA responses to 300 µM GABA before and after PTL
attachment indicate negligible changes in receptor activity during the experiment. Only
in the presence of externally applied GABA was the receptor activated, irradiation with
light did not trigger receptor activation. Attachment of the PTL to genetically engineered
cysteine mutant receptors created light-regulated GABAA receptors (LiGABARs).
To determine if cysteine substitution or PTL attachment affected receptor
sensitivity to GABA we investigated GABA sensitivity of untreated, MAM-6 treated αcysteine engineered mutant receptors to that of untreated wild-type α1β2 receptors or
wild-type α5β2 receptors.

The effect of MAM-6 attachment or engineered cysteine

residue substitution on receptor function was evaluated by quantifying the change in
current ratio elicited from responses to 3 µM to 3 mM GABA (Table 1). We determined
that the following cysteine mutation sites for α1: 41, 68, 171 had lower sensitivity to
GABA compared to wild-type and therefore these cysteine mutants were not optimal
sites for PTL attachment to study receptor subtype function in neurons because receptor
sensitivity was altered (Table 1). Further, the α1(T125C) mutation was chosen as the
optimal PTL attachment site because it allowed substantial photoregulation of α1 GABA
receptors without altering receptor sensitivity to GABA before or after PTL attachment
(Table 1). For α5 GABA receptors we determined the α5(S72C) mutation as the optimal
PTL attachment site.
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A. Supplementary Data

Figure 2.3. Attachment of Trans MAM-6 Inhibits Engineered GABAA
Fig.
S1. Trans MAM-6 inhibits a mutant GABA A R after conjugation. An oocyte
Receptors
!"#$!%%&'()*+,-+./012.)34%)5!%5!6)3&57)8)9:)4'6)8;;)9:)<=>=),black traces on the left).
The
oocyte was then
treated
50 µM
MAM-6from
for 10aminutes.
After
MAM-6
treatment,
Representative
trace
of with
GABA
responses
Xenopus
oocyte
expressing
α1(T125C)β2.
The
oocyte
was
first
exposed
to
3
µM
GABA
followed
by
300
µM
GABA,
the current at 3 µM GABA was reduced in 500-nm (green trace) but not in 380-nm
light
then treated
50 µM
for 10
minutes
allow
cysteine
tethering
of the
PTL.
(middle
purplewith
trace).
TheMAM-6
responses
evoked
by to300
?Mfor
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before
and after
MAM-6
After MAM-6
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irradiated
with 500
light during
µMcourse
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that the
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changewas
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over 3the
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followed
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the experiment. Neither 380-nm nor 500-nm light triggered receptor activation in the
finally treatment with 300µM GABA during irradiation with 380 nm light.
absence
of externally applied GABA.

2

30

Table S1. The GABA Sensitivity of Untreated and MAM-!"#$%&#%'"(-Mutants.
Table 1: GABA sensitivity of untreated and MAM-6 treated engineered α-mutants
mutation
site
!1
wildtype
41
68
121
125
171
!5
wildtype
72

I 500 /I 380
(mean ± SEM)a
1.08 ± 0.02
(untreated)
0.62 ± 0.03
0.47 ± 0.05
0.52 ± 0.03
0.60 ± 0.03
0.63 ± 0.03
1.01 ± 0.01
(untreated)
0.95 ± 0.10

MAM-6 attached receptor
I 3µM /I 3mM (380 nm)
trials
(mean ± SEM)b
9
10
8
14
10
4

-0.41
0.17
0.34
0.44
0.20

±
±
±
±
±

0.03
0.03
0.03
0.07
0.01

trials
--

0.46 ± 0.03

9

9
4
14
7
4

0.33
0.34
0.49
0.45
0.20

0.03
0.03
0.02
0.05
0.01

3
3
4
4
3

0.43 ± 0.01

7

0.39 ± 0.00

3

3
15

0.22 ± 0.02

untreated receptor
I 3µM /I 3mM
trials
(mean ± SEM)b

11

±
±
±
±
±

comments

c
c,d
d
e
c,d

a. Current ratio was measured at 3 µM GABA (500 nm vs. 380 nm).
ratio was
at 3attachment
µM GABA (500
vs. 380 nm).
b.a. Current
The effect
ofmeasured
MAM-6
ornm
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e. The receptor’s sensitivity to GABA is unaltered in 380 nm light after MAM-6
attachment. This feature makes α1(T125C) the best mutant for downstream
applications in neurons.

B. Supplementary Materials and Methods
B.1. Plasmid and virus preparation
!

Wild-type and mutant cDNAs

The cDNAs of rat GABA A D% &'% 8@A% () subunits (wild-type and mutants) are in
vector pGH19 (for oocytes), pCDNA3.1 (for HEK293T cells and oocytes), or pUNIV (for
HEK293T cells). The cysteine mutants &'(K70C) and &'(D123C) and wild-type subunits
(&'%8@A%()) were obtained in vector pGH19 from Professor Cynthia Czajkowski (University
of Wisconsin, USA). The wild-!"#$% &;% +?>?@*!% 48+% 3>!8*@$A% *@% E$C!32% #DFG% 1237% H26%
Hartmut Luddens (University of Mainz, Germany). The wild-!"#$%I)J%+?>?@*!%was obtained
in vector pUNIV from Professor Cynthia Czajkowski. :=$%K$@$+%31%&%8@A%(%+?>?@*!+%were
sub-cloned into vector pCDNA3.1 for expression in HEK293T cells. Other cysteine mutants
were prepared by site-directed mutagenesis in the wild-!"#$% &'% and &5 clones (in
pCDNA3.1). Mutations were confirmed by sequencing.
6
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2.2.4

Identification of critical PTL components for LiGABAAR control
To determine the critical components required for the PTL to photoregulate

GABA receptors of interest we altered the structure of the MAM-6 PTL design. Both the
muscimol ligand and spacer moieties of MAM-6 were altered and the resulting PTLs
were tested for their ability to photoregulate 10 µM GABA sensitivity of α1(T125C)
GABAA receptors or α5(S68C) GABAA receptors. Muscimol is negatively charged at
physiological pH, enabling receptor binding. Consistent with this mechanism, replacing
muscimol with a neutral analogue 4-hydroxylbenzylamine reduced the photoregulation
effect in α1(T125C) GABAA receptors; this PTL was named MAB-6 (Figure 2.4A, Figure
2.4B).

Photoregulation was nearly completely suppressed in α1(T125C) GABAA

receptors when the 6-carbon spacer of MAM-6 was removed; this PTL was named
MAM-0 (Figure 2.4A, Figure 2.4B). Surprisingly, removal of the 6-carbon spacer and
substituting muscimol with neutral analogue 4-hydroxylbenzylamine (MAB-0), increased
the photoregulation effect in α1(T125C) GABAA receptors, resulting in an effect greater
than that by MAM-6, suggesting that the muscimol ligand was not a required component
of the PTL design for photoregulation (Figure 2.4A, Figure 2.4B).

Interestingly,

α5(S68C) GABAA receptors were only photoregulated with MAM-6 attachment,
suggesting both a flexible linker and a negatively charged ligand are required for
photoregulation of α5 receptors (Figure 2.4C). In summary, screening of engineered
cysteine-mutant receptors and PTLs revealed the best combination for creating lightregulated GABAA receptors (LiGABARs) was α1(T125C) tethered to MAB-0 and
α5(S68C) tethered to MAM-6.
The strong photoregulation by MAB-0 suggests that its ligand binds strongly to the
GABA-binding pocket when the azobenzene is photoswitched to the trans isomer
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suggesting MAB-0 prevents GABA binding by blocking the GABA-binding site.

To

investigate the increased photoregulation effect of MAB-0 in α1(T125C) GABAA
receptors, we used molecular modeling to dock trans and cis MAB-0. Docking trans
MAB-0 in a homology model of α1(T125C)β2 dimer suggested that the PTL spans the
GABA binding site and the binding pocket (Figure 2.4D, top). Aromatic residues in the
GABA-binding pocket are indicated in yellow (Figure 2.4D). Trans-to-cis isomerization of
azobenzene retracts MAB-0 from the GABA binding site subsequently relieving receptor
antagonism (Figure 2.4D, bottom).
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A representative trace showing reversible photoregulation of the baseline level when a
ABAR-containing neuron was held at –60 mV. Photoregulation was abolished,

2.2.5

Photoregulation of mIPSC of α1- and α5-GABAA receptors
Once the optimal PTL design and attachment site for α1- and α5-GABAA

receptors was determined, we investigated if synaptic inhibition in primary neurons could
be controlled optically with these LiGABAARs. These experiments were to test if α1- and
α5-GABAA enable photoregulation of phasic and tonic inhibition. Primary dissociated
cultures of hippocampal neurons isolated from rat brains were transfected with a bicistronic construct encoding either α1(T125C) or α5(S72C), along with eGFP as a
transfection marker. When these neurons were synaptically active, between DIV 17-21
days, they were treated with MAB-0(α1) or MAM-6(α5) for 15 minutes. To investigate
phasic inhibition, we acquired whole-cell patch clamp electrophysiology recordings of
endogenous mini inhibitory postsynaptic currents (mIPSCs) from neurons expressing
α1(T125C) or α5(S72C) after PTL treatment (Figure 2.5A).

Both α1(T125C) or

α5(S72C) LiGABAARs enabled photoregulation of endogenous mIPSCs. The amplitude
of the mIPSC were increased upon irradiation with 380 nm light when the PTL was in the
retracted cis conformation whereas the amplitude decreased upon irradiation with 500
nm light when the PTL was in the extended trans conformation (Figure 2.5A, Figure
2.5B). To quantify the amount of photoregulation, the average mIPSC when the PTL
was in cis or trans conformation was calculated. Neurons with α1(T125C)-LiGABAARs,
cis-to-trans photoisomerization had a 38 ± 2% decrease in peak amplitude and a 57 ±
4% decrease in total charge transfer (n = 6, P < 0.001; Figure 2.5B, Figure 2.5C).
Neurons with α5(S72C) LiGABAARs cis-to-trans photoisomerization had a 29 ± 3%
decrease in peak amplitude and 34 ± 4% decrease in total charge transfer (n = 6, P <
0.001; Figure 2.5B, Figure 2.5C).
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Figure 2.5. LiGABAAR Mediated Photoregulation of mIPSCs
A) Representative traces of mIPSC recordings from a cultured hippocampal neuron
containing MAB-0 tethered to α1(T125C) subunits (top) or MAM-6 tethered to α1(S68C)
subunits (bottom). Neurons were held at -60 mV. To convert the PTL to its cis isomer,
cells were exposed to 380 nm light for 5 seconds, then no light where the majority of the
PTL remains in the cis conformation.
B) Representative average mIPSC traces when the PTLs were in the trans (green trace)
or cis (violet trace) conformation from the cells shown in A. MAB-0 tethered to
α1(T125C) subunits (top panel) or MAM-6 tethered to α1(S68C) subunits (bottom
panel).
C) Group data (mean ± S.E.M.) of mIPSC photoregulation in cultured hippocampal
neurons (n = 6 for each isoform). The degree of photoregulation was quantified as the
percent decrease (in peak amplitude or charge transfer) when the PTL was
photoswitched from cis to trans.
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2.2.6

MAB-O selectivity
Control experiments were completed to confirm that PTL were target-specific and

did not photoregulate or confer light sensitivity on wild-type neurons.

These control

experiments were completed to confirm off-target receptors were not altering their
function in response to light. These controls were necessary because the PTL contains
a maleimide moiety could potentially allow for cysteine tethering to receptors containing
endogenous cysteine residues.

Treatment of PTL on wild-type neurons did not

photoregulate wild-type GABAA receptors, ionotropic glutamate receptors, or voltagegated channels, confirming that photocontrol is specific to the engineered LiGABAAR
(Figure 2.6). The designed PTL only photosensitizes the mutant receptor containing the
α subunit of interest.
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Figure
2.6. MAB-0 Treatment Does Not Photosensitize Endogenous Ligand-gated
!
or Voltage-gated Ion Channels
A) Average mIPSC traces from representative neuron following MAB-0 treatment does
not photosensitize endogenous GABAARs in cultured hippocampal neurons. I500/I380 =
1.00 ± 0.02 (Vhold = –60 mV; n = 3, P = 0.87).
B) Average mEPSC from representative neuron following MAB-0 treatment does not
photosensitize endogenous GABAARs in cultured hippocampal neurons. I500/I380 = 0.97
± 0.10 (Vhold = –70 mV; n = 4, P = 0.64).
C) MAB-0 treatment does not photosensitize endogenous AMPARs in a hippocampal
slice. Evoked EPSC traces from a CA1 pyramidal neuron are shown. I500/I380 = 1.02 ±
0.01 (Vhold = –70 mV; n = 4, P = 0.2).
D) MAB-0 treatment does not photosensitize endogenous NMDARs in a hippocampal
slice. Evoked EPSC traces from a CA1 pyramidal neuron are shown. Currents were
measured 100ms after the stimulus. I500/I380 = 0.95 ± 0.04 (Vhold = +40 mV; n = 3, P =
0.3).
E) MAB-0 treatment does not photosensitize endogenous voltage-gated Na+ channels.
Inward currents (elicited by a 200-ms depolarization to –10 mV) from a representative
neuron are shown. I500/I380 = 0.99 ± 0.05 (Vhold = –70 mV; n = 4, P = 0.87).
F) MAB-0 treatment does not photosensitize native voltage-gated K+ channels. Voltagegated K+ currents (elicited by a 200-ms depolarization to +40 mV) from a representative
neuron are shown. I500/I380 = 0.98 ± 0.05 (Vhold = –70 mV; n = 4, P = 0.43).
All traces in 380 nm and 500 nm are shown in violet and green colors, respectively.
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2.2.7

Photocontrol of neuron excitability
The goal of designing PTL to target subtype specific α receptors was to discover

the function of GABAA receptor subtypes in synaptic neurotransmission using
photochemical tools for precise and selective manipulation of specific subtypes of
GABAA receptors.

GABAA receptors have a crucial function in preventing runaway

neuronal excitation. Pharmacological inhibition or knock-out of GABAA receptors are
known to alter GABAA function and result in epileptic brain activity. To determine if
epileptic activity can be induced by photo-antagonizing α1(T125C) LiGABAAR in intact
brain tissue we introduced α1(T125C) LiGABAAR into hippocampal brain slices using
AAV. After MAB-0 treatment we applied a train of presynaptic stimuli and recorded
action potential firing of neurons irradiated with 380 nm and 500 nm light. Photocontrol
of neural inhibition of α1(T125C) LiGABAAR irradiated with 500 nm light where the PTL
was in an extended confirmation led to photocontrol α1(T125C) LiGABAAR

that

prevented of action potential firing, a characteristic of epileptiform activity (Figure 2.7).
Irradiation of the α1(T125C) LiGABAAR with 380 nm reversed this effect enabling action
potential firing and prevention of epileptic activity (Figure 2.7).
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Figure 2.7. LiGABAA Receptors Enable Photocontrol of Neuron Excitability
Whole-cell current-clamp recording of CA1 pyramidal neuron expressing α1(T125C)
receptors treated with MAB-0 enabled photocontrol of neuron excitability. Irradiation
with 500 nm light resulted in an “epileptic” plateau preventing action potential firing that
was reversed upon irradiation with 380 nm light. Traces in 380 nm shown in violet and
500 nm are shown in green.
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2.3 Discussion
We developed a series of LiGABAAR that enable light-controlled inhibitory
neurotransmission.

The α1- and α5-LiGABAARs developed here are distinct from

previously developed photochemical tools for manipulating neural inhibition such as
caged GABA in that LiGABARs allow specificity and for native forms of inhibitory
neurotransmission to be controlled by light. The LiGABAARs developed here provide a
unique

opportunity

for

spatiotemporal

precision

mechanisms of subtype-specific neural inhibition.

to

investigate

the

underlying

Designing PTLs and genetically-

engineering GABAA receptors enabled specific spatiotemporal precision to investigate
and manipulate receptor-subtype contributions in inhibitory neurotransmission. We have
developed a method for photocontrolling GABAA receptors that is fast, reversible and
subtype-specific.
PTLs have the ability to target surface exposed cysteines on endogenous
receptors and engineered-cysteine substituted receptors.

The results of our

experiments showed that our PTLs only conferred light-sensitivity and photocontrol on
engineered receptors.

Wild-type GABAA receptors and other off-target ion-channels

were not photoregulated by these PTLs demonstrating that the PTLs in our experiments
were specific to receptor subtypes of interest. Further, cysteine substitutions of α1 and
α5 GABAA receptors with subsequent PTL attachment enabled photocontrol of GABAA
receptors. PTL attachment sites had varying degrees of photocontrol. The optimal PTL
attachment site and subsequent PTL attachment enabled substantial photocontrol of
inhibitory neurotransmission without altering the receptors GABA sensitivity.
The results illustrate tethered muscimol acts as an antagonist when the PTL is
irradiated with 500 nm light on genetically-engineered cysteine substituted GABAA
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receptors. The PTL design was based on reports that muscimol conjugates in which the
amino group was linked to biotin or a fluorophore remained a GABAA receptor agonists
(Vu et al., 2005).

Receptor antagonism by tethered muscimol may be the result of

changes to the moiety that render unable to induce protein conformation changes
required for channel gating. Loss of the critical ammonium group of agonists are know
to prevent hydrogen bonding which prevents changes required for channel gating
(Cromer et al., 2002). The tethering of muscimol due to N-acylation leads to the loss of
an ammonium group that may disrupt conformational changes required for channel
gating. Additionally, the PTL may disrupt binding at the α-β interface by blocking or
restricting binding at the GABA-binding site. In fact, removal of the muscimol ligand and
the flexible linker in MAB-0 enabled precise photocontrol of genetically engineered α1
receptors suggesting delivery of a terminal phenol group to the GABA-binding site can
disrupt channel gating. Further modifications to PTL designs that provide functional
groups that interact more favorably with the GABA-binding site have the potential to
enhance the photoregulation effect of PTLs.
Hippocampal neurons expressing LiGABAAR enabled photoregulation of
endogenous mIPSCs. Subtype-specific LiGABAAR enable investigation into the role α1
and α5 have in mediating phasic and tonic inhibition. LiGABAAR photoregulation will
provide a precise method to investigate the distribution of sub-type specific receptors
and examine their functional role in leaning and memory. Additionally LiGABAAR in
intact hippocampal brain slices enabled photocontrol of action potential firing. This result
suggests that LiGABAAR can be utilized to exert light-switchable control on native
receptors in the brain to investigate the role specific subtypes of GABAA receptors have
in preventing epilepsy.
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2.4 Methods
2.4.1
2.4.1.1

Plasmid preparation
Wild-type and mutant cDNAs
The cDNAs of wild-type rat GABAAR α1 (in pGH19), β2 (in pGH19), and γ2S (in

pUNIV) were obtained from Professor Cynthia Czajkowski (University of Wisconsin,
USA). The α5 wildtype subunit was obtained in vector pRK7 from Dr. Hartmut Luddens
(University of Mainz, Germany). The genes of α and β subunits were sub-cloned into
vector pCDNA3.1(-) for expression in HEK293T cells and Xenopus oocytes. Mutants
α1(K70C) and α1(D123C) (in pGH19) were obtained from Professor Cynthia Czajkowski
(University of Wisconsin-Madison).

Other cysteine mutants were prepared by site-

directed mutagenesis of the wild-type α1 and α5 clones in pCDNA3.1(-) using
oligonucleotide primers under the following PCR profile: 1 cycle (95°C for 30s); 18 cycles
(95°C for 50s, 60°C for 50s, 68°C for 9min); 1 cycle (68°C for 7min). Mutations were
confirmed by sequencing.
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2.4.1.2

Adeno-associated virus construction of pAAV-hSyn-EGFP-2A-mycα1(T125C)
The construct is designed to express GFP and α1(T125C) in a 1:1 ratio using the

2A protein sequence (GSGATNFSLLKQAGDVEENPGP) (Provost et al., 2007) and to
restrict expression to neurons using the human synapsin promoter (Kugler et al., 2003).
The vector also contains terminal repeats (TR) and woodchuck hepatitis posttranscriptional regulatory element (WPRE) for packaging into the adeno-associated virus
(AAV). The human synapsin promoter was chosen because it allows powerful neuronspecific expression of genes, and is easily delivered via an adenoviral vector. Human
synapsin 1 gene promoter confers highly neuron-specific long-term transgene
expression from an adenoviral vector in the adult rat brain depending on the transduced
area (Kugler et al., 2003).

The myc epitope (protein sequence EQKLISEEDL) was

inserted into the α1(T125C) subunit as previously described (Connolly et al., 1996).
The pAAV vector backbone was digested with NheI and HindIII and ligated with the 2Aα1 and GFP-2A fragments. The final construct was confirmed with sequencing.

2.4.1.3

Preparation of Adeno Associated Virus (AAV)
AAV9 encoding GFP-2A-α1(T125C) produced by plasmid co-transfection into

HEK293T cells as described previously (Choi et al., 2007). After ultracentrifugation, the
interphase between the 54 and 40% iodixanol fraction, and the lower three-quarters of
the 40% iodixanol fraction, were extracted and diluted with an equal volume of
phosphate- buffered saline (PBS) plus 0.001% Tween 20. This fraction was then buffer
exchanged and concentrated with Amicon Ultra-15 Centrifugal Filter Units to a final
volume of ~100 µL. The α1(T125C) AAV titered was 7.5 × 1012 vg/mL.
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2.4.2

Cell culture, Mutant Expression and PTL treatment

2.4.2.1

Xenopus oocytes

RNA was prepared with the mMessage mMachine T7 kit (Ambion, Austin, TX).
Defolliculated Xenopus laevis oocytes were injected with 2.5–20 ng of mRNA in 50 nL
H2O in a 1:1 ratio of α to β subunit RNA. The injected oocytes were incubated at 18°C
(in OR1 buffer) and subjected to two-electrode voltage-clamp recording 1–3 days after
RNA injection. The OR1 buffer comprised (in mM): 96 NaCl, 2 KCl, 1.8 CaCl2, 1 MgCl2,
5 HEPES; pH 7.4.

For testing MAM-6 mediated photo-control of receptor activities,

oocytes expressing cysteine substituted α1 or α5 mutants were incubated with 50 µM
MAM-6 for 0.5–1.5 hr prior to recording.

2.4.2.2

HEK293T cells

HEK293T cells were maintained in Dulbecco’s Minimum Essential Medium
(DMEM) (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS) at
37°C and 5% CO2. Cells were plated at 18–24 × 103 cells/cm2 on poly-L-lysine coated
coverslips and transfected by calcium phosphate precipitation. A total of 0.9 µg DNA per
coverslip (α1:β2:eGFP at 4:4:1 ratios) was added to the cells.

Recordings were

performed 36 to 48 hours post-transfection. For attaching PTL to the mutant receptors,
cells were treated with dithiothreitol (DTT; 1 mM, 5 min), incubated in fresh external
recording solution (5 min), and then treated with PTL (25 µM, 20 min, pH 8) at 37°C in
the dark. Whole-cell voltage-clamp recordings were performed thereafter.

45

2.4.2.3

Dissociated hippocampal neurons

Primary cultures of neonatal rat hippocampal neurons were performed using
standard procedures, as previously described (Fortin et al., 2008). Cells were grown in
minimum essential medium (MEM) containing 5% FBS, 20 mM
(Invitrogen), 2 mM

glucose, B27

glutamine and Mito+ Serum Extender (BD Biosciences).

Transfection was performed via calcium phosphate precipitation 6–7 days after plating.
Whole-cell electrophysiology recordings at 3 weeks after plating.

2.4.2.4

Organotypic hippocampal slice cultures
Postnatal day 8 Sprague-Dawley rat pups were anaesthetized and decapitated.

Hippocampi were removed and sliced into 350 µm thick sections using a tissue chopper
(Stoelting, Wood Dale, IL).

Slices were maintained at 34°C on cell culture inserts

(Milipore, Billerica, MA) in Neurobasal-A medium (Invitrogen) supplemented with 20%
horse serum (Thermo Scientific, Waltham, MA), 0.03 units/ml insulin (Sigma, St. Louis,
MO), 0.5 mM ascorbic acid (Sigma), 1X Gluta-Max (Invitrogen), 80units/ml penicillin,
80µg/ml streptomycin (Invitrogen), and 25 mM HEPES.

One day after preparation,

slices were injected with AAV9 encoding GFP-2A-α1(T125C). The CA1 pyramidal cell
body layer was injected at 3–7 sites/slice with 100nl of 1012-1013 vg/ml virus with a fine
glass pipette. 5–14 days post-injection, slices were incubated for 2 min with 1 mM
Tris(2- carboxyethyl)phosphine hydrochloride in artificial cerebrospinal fluid (ACSF)
containing in mM: 126 NaCl, 2.5 KCl, 1.25 NaH2PO4, 10 Glucose, 1.3 MgCl2, 26
NaHCO3 and 2.5 CaCl2 equilibrated with 95% O2/5% CO2, washed, and incubated with
25 µM MAB-0 in ACSF for 30min at room temperature. The PTL treated slices were
subjected to whole- cell current-clamp recording.

46

2.4.3

Electrophysiology

2.4.3.1

Two-electrode voltage-clamp of Xenopus oocytes

Single oocytes were placed in a 0.2-mL perfusion chamber and impaled with two
glass microelectrodes (1–2.5MΩ resistance) filled with 3M KCl and voltage clamped with
an OC-725C amplifier (Warner Instruments, Hamden, CT) in OR1 solution containing (in
mM): 96 NaCl, 2 KCl, 1.8 CaCl2, 1 MgCl2, 5 HEPES; pH 7.4. Oocytes were held at
-80 mV. Drug perfusion, data acquisition, and analysis were carried out with pClamp
software and a Digidata 1200 interface (Molecular Devices, Sunnyvale, CA). Oocytes
were illuminated by a Lambda DG-4 (Sutter Instruments, Novato, CA) using 383 nm and
497 nm filters.

2.4.3.2

Whole-cell voltage-clamp of HEK293T cells

Recordings were performed using pipettes with 2.5–4 MΩ resistance. Pipettes
were pulled from filamented borosilicate pipettes (G150TF-3, Sutter Instruments).
Extracellular solution contained (in mM): 140 NaCl, 5 KCl, 1 MgCl2, 10 HEPES, 2 CaCl2,
10 glucose; pH 7.4.

Intracellular solution contained (in mM): 140 CsCl, 4 NaCl, 10

HEPES, 2 MgCl2, 2 Mg-ATP, 10 EGTA; pH 7.2. Cells were held at –70 mV. Signals
were amplified using a Patch Clamp PC-505A amplifier (Warner Instruments), digitized
by a Digidata 1322A converter (Molecular Devices), and acquired with software Clampex
10 (Molecular Devices).

Illumination for PTL photoisomerization was provided by a

Lambda-LS xenon lamp (Sutter Instruments) with band pass filters (379 ± 17 nm and
500 ± 8 nm).
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2.4.3.3

Whole-cell voltage-clamp of dissociated hippocampal neurons

Voltage-clamp recordings were performed at room temperature using standard
whole cell patch-clamp techniques. Signals were amplified using a Patch Clamp PC505B amplifier (Warner Instruments), filtered at 2kHz, digitized at 10kHz using a Digidata
1200 converter (Molecular Devices), and acquired using Clampex 8 (Molecular Devices).
To record spontaneous mIPSCs, cells were held at –60 mV. The extracellular
solution contained (in mM): 138 NaCl, 1.5 KCl, 1.2 MgCl2, 2.5 CaCl2, 5 HEPES, 10
Glucose, 0.001 TTX (to block voltage-dependent Na+ channels), 0.025 DNQX (to block
AMPA receptors), and 0.05 APV (to block NMDA receptors); pH 7.4.

The internal

solution contained (in mM): 140 CsCl, 4 NaCl, 2 MgCl2, 10 HEPES, 10 EGTA, 2 MgATP; pH 7.4
To record spontaneous mEPSCs, cells were held at –70 mV. The extracellular
solution contained (in mM): 138 NaCl, 1.5 KCl, 1.2 MgCl2, 2.5 CaCl2, 5 HEPES, 10
Glucose, 0.001 TTX, 0.02 bicuculline; pH 7.4.

The internal solution contained (in mM):

8 NaCl, 135 K-gluconate, 4 MgCl2, 10 HEPES, 2 Mg-ATP, 1 EGTA; pH 7.4.

All

miniature events were detected using the software MiniAnalysis (Synaptosoft, Decatur,
GA) and were verified visually. The search protocol threshold was set at fivefold the
root-mean-square (RMS) noise level, which typically was 2–5 pA.
For recording voltage-gated currents, extracellular solution contained (in mM): 138
NaCl, 1.5 KCl, 1.2 MgCl2, 2.5 CaCl2, 5 HEPES, 10 Glucose, 0.02 bicuculine, 0.025
DNQX, and 0.05 APV; pH 7.4. The internal solution contained (in mM): 10 NaCl, 135 Kgluconate, 2 MgCl2, 10 HEPES, 1 EGTA, 2 Mg-ATP; pH 7.4. Cells were held at –70 mV
and stepped for 200ms to values between –100 and +40 mV, with increment steps of 10
mV.
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2.4.3.4

Whole-cell current-clamp recording of hippocampal slices
Slices were placed in a recording chamber mounted on an Olympus BX51WI

microscope and perfused with ACSF at RT at 1–2 ml/min. Whole-cell current clamp
recordings were made from CA1 pyramidal cells with glass microelectrodes (R = 4–7
MΩ) filled with internal solution containing (in mM): 116 K-gluconate, 20 HEPES, 6 KCl,
2 NaCl, 0.5 EGTA, 4 ATP-Mg, 0.3 GTP-Na, ~ 7.2 pH, ~290mOsm. A glass stimulating
electrode was placed in stratum radiatum 300–500 µm away from the recorded cell.
Synaptic responses were evoked by a 0.2 ms, 10–100 µA current pulse delivered via a
stimulus isolation unit (AMPI, Jerusalem, Israel). To record evoked IPSPs cells were
depolarized to -45mV by somatic current injection. Signals were amplified (Axopatch,
Molecular Devices), digitized (Digidata, Molecular Devices) and recorded (pClamp,
Molecular Devices) to computer. Light was delivered through the microscope optical
port by a Polychrome (Till Photonics, Munich, Germany) controlled by pClamp.
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2.4.4

Molecular Modeling
Docking of trans- and cis-MAB-0 was carried out in the docking program GLIDE

(Shrödinger Inc., Portland, OR) (Korpi et al., 2002), implemented in Maestro (Shrödinger
Inc.). A dimer of α1 and β2 subunits from a previously published homology model for
GABAA receptor (α1β2γ2) was used (O'Mara et al., 2005). Threonine residue 125 of the
α1 subunit was replaced by a cysteine residue, and a receptor grid was created based
on a dimmer with this α1 mutation. Trans- and cis-MAB-0 were individually docked in
the grid using the Standard Precision algorithm. To mimic MAB-0 tethering, a positional
constraint was applied during docking.

This constraint enforced at least one of the

reactive carbons (of the maleimide) of MAB-0 to locate within 4.5 Ǻ from the cysteine
side-chain carbon. A maximum of 100 poses were listed. The docking poses were
further inspected visually to remove unreasonable results. All of the docking poses for
trans-MAB-0 insert the azobenzene moiety in the αβ interface.

The predominant

docking mode of trans-MAB-0 is shown in Figure 2.4D top, in which the terminal phenol
group of trans-MAB-0 reaches deeply into the GABA-binding site (surrounded by several
aromatic residues represented in yellow). The docking poses for cis-MAB-0 are fewer
and more diversely oriented. The majority of the cis poses place the terminal phenol
group outside of the aromatic region of the GABA-binding site. The bottom of Figure 2D
bottom presents a docking pose of cis-MAB-0 that has a similarly positioned maleimide
group to that of the trans pose, showing the change in the molecular shape and the
accessibility of the phenol group when MAB-0 is switched from trans to cis conformation.
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CHAPTER 3

INCREASED HDAC6 EXPRESSION ALTERS TAU AND PP1 PROTEIN LEVELS

3.1 Introduction
HDAC6 is a protein that has multiple roles in the cytosol.

This protein is a

versatile multifunctional enzyme responsible for deacetylating key proteins involved in
protein degradation pathways, cellular stress, and cytoskeletal dynamics (d'Ydewalle et
al., 2012; Li et al., 2013; Parmigiani et al., 2008; Zhang et al., 2013). The role of HDAC6
in neurodegenerative disease is controversial. It is unclear if the observed increases in
HDAC6 protein levels in the AD brain are the result of a neuroprotective response to
eliminate protein aggregates or an underlying causative agent in AD pathology and
progression. The experiments described here were devised to investigate the role of
HDAC6 in AD tau pathology.

A heterologous mammalian cell culture system was

utilized to assess the role of HDAC6 in a simplified system in which genes can be easily
delivered and expressed. The goal of this chapter is to determine if increased HDAC6
protein levels lead to increased pathological tau accumulation and if disrupting an
HDAC6-PP1 interaction decreases pathological tau.
Tau is a microtubule-associated protein (MAP), primarily expressed in neurons
that promotes microtubule assembly and stabilization (Iqbal et al., 2005). Tau plays a
key role in regulating cytoskeletal microtubule dynamics, axonal transport and neurite
outgrowth and all of these functions are modulated by site-specific phosphorylation
(Johnson and Stoothoff, 2004).

Under normal physiological conditions, tau is in a

constant equilibrium, on and off the microtubules (Ballatore et al., 2007; Dixit et al.,
2008). The enzymatic activity of phosphatases and kinases control this equilibrium of
microtubule-binding affinity by regulating the phosphorylation state of tau at serine and
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threonine residues (Ballatore et al., 2007). Tau phosphorylation is catalyzed by protein
kinases and dephosphorylated by protein phosphatases. An imbalance of protein kinase
and protein phosphatase activity can lead to tau hyperphosphorylation.

One key

phosphatase, protein phosphatase 1 (PP1) has been shown to interact with HDAC6 and
this interaction is believed to disrupt the ability of PP1 to dephosphorylate tau leading to
an increase in the accumulation of pathological hyperphosphorylated tau (Brush et al.,
2004; Ding et al., 2008).
The human tau gene, located on chromosome 17, is alternatively spliced to
generate six different isoforms. The tau isoforms differ by having three repeat (3R) or
four repeat (4R) microtubule-binding domains in the C-terminal and the presence or
absence of exons 2 and 3 in the N-terminal (Buee et al., 2000; Johnson and Stoothoff,
2004). Healthy adult human brains contain approximately a 1:1 ratio of the 3R tau and
4R tau isoforms. Deviations from this 1:1 ratio are associated with neurodegenerative
disease (Andorfer et al., 2003; Ballatore et al., 2007). Since tau is primarily expressed in
the brain, an established heterologous system that stably expresses tau was required for
these experiments.
Human embryonic kidney cells (HEK) stably expressing tau (HEK-tau) were
chosen as the cell-line for these experiments because they stably express human tau
isoforms with four microtubule binding repeats without exon 2 and 3 (Ding et al., 2008;
Cho and Johnson, 2003).

These HEK-tau cells have been used to investigate tau

phosphorylation in the presence of endogenous HDAC6 and disruption of the catalytic
activity of HDAC6 by domain-selective small-molecule inhibitor tubacin or shRNA
knockdown of HDAC6 in these cells was found to attenuate tau phosphorylation (Ding et
al., 2008).

The experiments in this chapter were designed to assess if HDAC6

overexpression altered tau pathology, and to examine PP1 levels in HEK-tau cells
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expressing catalytically inactive HDAC6 or catalytically active HDAC6. In order to target
the catalytic domains of HDAC6 without altering protein folding or truncating the protein,
established single-point mutations to render HDAC6 catalytically inactive were used
(Brush et al., 2004; Ding et al., 2008; Haggarty et al., 2003).

3.2 Results
3.2.1

Overexpression HDAC6 alters tau protein levels
To assess if HDAC6 overexpression had an effect on the accumulation of

pathological tau in a heterologous expression system, HEK-tau cells were transfected
with human HDAC6.

Additionally single point mutations that rendered each of the

catalytic domains of HDAC6 inactive, and a double mutant with both catalytic domains
inactive were created. Mutant HDAC6 constructs were created to assess if functional
HDAC6 was responsible for increased tau phosphorylation and if disruption of an
HDAC6-PP1 interaction attenuated tau phosphorylation. Cells were lysed 36 hrs posttransfection, total protein was separated by SDS-PAGE and then immunoblotted. The
monoclonal Tau-5 antibody was used to detect total tau (both phosphorylated and nonphosphorylated forms of tau) (Tau-5, Invitrogen), a monoclonal FLAG antibody to verify
HDAC6 expression (FLAG, Stratagene) and GAPDH as a loading control (GAPDH,
SantaCruz). HEK-tau cells overexpressing HDAC6 were found to have increased total
tau protein levels of high-molecular weight compared to wild-type HEK-tau control cells
(Figure 3.1). HDAC6 overexpression in HEK-tau cells led to a 2.4 fold increase in total
tau compared to wild-type HEK-tau control cells.

Unexpectedly, HEK-tau cells

overexpressing catalytically inactive HDAC6 mutants: H216A, H611A, and double
mutant H216AH611A all had increased total tau protein levels of high-molecular weight
(Figure

3.1)

suggesting

increased

accumulation
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of

hyperphosphorylated

tau

accumulation compared to wild-type HEK-tau control cells.

Mutant HDAC6

overexpression in HEK-tau cells led to an total tau increase of 2.2 fold in H216A mutant
expressing cells, a 2.0 fold increase in total tau in H611A mutant expressing cells, and a
2.3 fold increase of total tau in catalytically inactive double mutant H216AH611A
expressing cells compared to wild-type HEK-tau control cells.

54

.'

4'
Tau-5 in HEKtau cells

0,.4)'
0)22.'

P = 0.0157

032).'

P = 0.0123

032).0)22.'

P = 0.0131
P = 0.0002

Tau-5 normalized

>'

56
7$
8
0, 9"7
.4 :'
03 )'
2)
.
0) '
22
.
03 '
2)
.0
)2
2.
'

3

;<.-&'21=+,"''

***

*

*

*

2

1

H
61
1A

db
lH

21
6A

H
61
1A

H
21
6A

C
A
D
H

no

n-

tr

an

s

6

0

!"#$%&'%($)*+,"''

-./,0&'1)+,"''

Figure 3.1. Increased HDAC6 Expression Alters Tau Protein Levels
A) Schematic of FLAG-tagged HDAC6 constructs.
B) Proteins isolated from cell lysates of wild-type non-transfected HEK-tau control cells
and HEK-tau cells transiently expressing HDAC6 constructs were separated by SDSPAGE and immunoblotted with mouse anti-FLAG (top-panel), mouse anti-Tau-5 (middlepanel), and rabbit anti-GAPDH (bottom-panel). Approximate molecular mass in kDa are
shown next to representative blots.
C) Quantification of Tau-5 from wild-type non-transfected HEK-tau control cells and
HEK-tau cells transiently expressing HDAC6 constructs plotted as mean ± S.E.M from at
least 4 separate experiments are indicated.
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3.2.2

Overexpression HDAC6 reduces PP1 protein levels
Next, HEK-tau cells overexpressing wild-type and mutant HDAC6 constructs

were utilized to determine if the increase in hyperphosphorylated high-molecular weight
tau was the result of altered PP1 protein levels or the enzymatic activity of PP1. The
monoclonal PP1 E-9 antibody was used to detect PP1 (PP1, SantaCruz) and GAPDH as
a loading control (GAPDH, SantaCruz).

HEK-tau cells overexpressing HDAC6 had

decreased PP1 protein levels compared to wild-type HEK-tau control cells (Figure 3.2).
HDAC6 overexpression in HEK-tau cells led to a 1.55 fold decrease in PP1 protein
levels compared to wild-type HEK-tau control cells.

Additionally, HEK-tau cells

overexpressing catalytically inactive HDAC6 mutants: H216A, H611A, and double
mutant H216AH611A all revealed decreased PP1 protein levels compared to wild-type
HEK-tau cells (Figure 3.2).

Mutant HDAC6 overexpression in HEK-tau cells led to

decreased PP1 levels of 1.19 fold in H216A mutant expressing cells, a 1.32 fold
decrease in PP1 in H611A mutant expressing cells, and a 1.61 fold decrease in PP1 in
catalytically inactive double mutant H216AH611A expressing cells compared to wild-type
HEK-tau control cells.

These decreases in PP1 protein levels correlated with the

increased accumulation of hyperphosphorylated high-molecular weight tau accumulation
in these cells suggesting reduction in the amount of available PP1 to dephosphorylate
tau leading to the pathological accumulation of tau in cells overexpressing both wild-type
and catalytically inactive HDAC6.

Interestingly, overexpression of either catalytically

inactive or wild-type HDAC6 led to decreased PP1 protein levels, revealing HDAC6
catalytic activity was not necessary for altering PP1 homeostasis.
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Figure 3.2. Increased HDAC6 Expression Alters PP1 Protein Levels
A) Schematic of FLAG-tagged HDAC6 constructs.
B) Proteins isolated from cell lysates of wild-type non-transfected HEK-tau control cells
and HEK-tau cells transiently expressing HDAC6 constructs were separated by SDSPAGE and immunoblotted with mouse anti-PP1 (top-panel), and rabbit anti-GAPDH
(bottom-panel). Approximate molecular mass in kDa are shown next to representative
blots.
C) Quantification of PP1 from wild-type non-transfected HEK-tau control cells and HEKtau cells transiently expressing HDAC6 constructs plotted as mean ± S.E.M from at least
4 separate experiments are indicated.
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3.2.3

Catalytically inactive HDAC6 does not deacetylate α-tubulin
The second catalytic domain of HDAC6 has been shown to be responsible for

cytosolic deacetylase functions of HDAC6. Therefore, to confirm that mutations to the
second catalytic domain rendered HDAC6 catalytically inactive HEK-tau cells
overexpressing wild-type and mutant HDAC6 constructs were used to assess levels of a
well-known protein substrate, α-tubulin. The monoclonal acetylated α-tubulin 6-11B-1
antibody was used to detect levels of acetylated tubulin (Acetylated-tubulin, Sigma) and
GAPDH as a loading control (GAPDH, SantaCruz).

As expected, the single-point

mutation H611A of the second catalytic domain of HDAC6 rendered the enzyme inactive
and thus unable to deacetylate α-tubulin (Figure 3.3). This result confirmed that only
mutations to the second catalytic domain rendered HDAC6 catalytically inactive.
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Figure 3.3. Mutations to the Second Catalytic Domain of HDAC6 Render HDAC6
Catalytically Inactive and Unable to Deacetylate Tubulin
A) Schematic of FLAG-tagged HDAC6 constructs.
B) Proteins isolated from cell lysates of wild-type non-transfected HEK-tau control cells
and HEK-tau cells transiently expressing HDAC6 constructs were separated by SDSPAGE and immunoblotted with anti-Acetylated Tubulin (top-panel), and anti-GAPDH
(bottom-panel). Approximate molecular mass in kDa are shown next to representative
blots.
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3.3 Discussion
In the present study, overexpression of HDAC6 was identified as a potential
underlying molecular factor altering both tau and PP1 protein levels. The data presented
here show that increased HDAC6 expression in a heterologous expression system leads
to increased tau accumulation (Figure 3.1) that correlates with decreased PP1 (Figure
3.2). Further, recent publications have shown reduction or loss of HDAC6 alleviates
abnormal tau accumulation and reduces cognitive deficits in a mouse model for
Alzheimer’s disease (AD) (Cook et al., 2012; Govindarajan et al., 2013; Xiong et al.,
2013). These data suggest that HDAC6 may be a novel target for potential therapeutic
of AD.
To date, the available broad-spectrum HDAC inhibitors and HDAC6 specific
inhibitors target the deacetylase enzymatic activity (Dallavalle et al., 2012; Haggarty et
al., 2003; Inks et al., 2012; Xu et al., 2011). Therefore experiments were designed to
determine the effect of catalytically inactive HDAC6 on tau and PP1 protein levels.
Inactivation of HDAC6 catalytic domain did not reverse the increase in pathological tau
accumulation (Figure 3.1).

Further, HEK-tau cells expressing catalytically inactive

HDAC6 resulted in reduced PP1 protein levels that were comparable to cells
overexpressing functional HDAC6 thus revealing enzymatic activity of either catalytic
domain of HDAC6 is not required for altering PP1 levels.

These data suggest that

inhibitors that target the catalytic domain of HDAC6 will not be an effective therapeutic
strategy in altering the accumulation pathological tau in AD.
Interestingly, Brush et al. reported that increased HDAC6 led to decreased
phosphatase activity in a dose-dependent manner (Brush et al., 2004). The second
catalytic domain of HDAC6 has been shown to be responsible for interacting with the
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catalytic domain of PP1 suggesting that HDAC6 deacetylates PP1 and regulates its
enzymatic activity (Brush et al., 2004). It was unexpected that PP1 levels were reduced
in HEK-tau cells overexpressing both catalytically active and inactive HDAC6. The data
presented here suggest that an HDAC6-PP1 interaction at the second catalytic domain
of HDAC6 is not responsible for the reduction in PP1 activity. Previously, Ding et al.
reported that by selectively inhibiting the enzymatic activity of the second catalytic
domain of HDAC6 with tubacin or shRNA knockdown of HDAC6 decreased the amount
of phosphorylated tau and suggested this was the result of the disruption of an HDAC6PP1 interaction (Ding et al., 2008). The data reported here suggests that increased
expression of HDAC6 leads to decreased PP1 protein levels and that this reduction in
PP1 may lead to increased accumulation of pathological phosphorylated tau.

Both

pathological tau accumulation and reduction in phosphatase levels are hallmarks of AD.
Acetylated tubulin is a marker of stable microtubules. HDAC6 deacetylates αtubulin thus decreasing the level of acetylated tubulin and reducing the stability of
microtubules. Disruption of the microtubule network is a central pathological mechanism
leading to neuronal dysfunction in neurons (Janke and Bulinski, 2011; Zhang et al.,
2013). Interestingly, tau has been reported to be an inhibitor of the deacetylase function
of HDAC6 (Perez et al., 2009). Therefore experiments were designed to determine if
HEK-tau cells that stably express tau inhibit the deacetylase function of HDAC6. HEKtau cells expressing HDAC6 with a functional second catalytic domain (HDAC6 and
H216A mutant HDAC6) had deacetylated tubulin levels confirming tau expression did
not inhibit the deacetylase function of HDAC6 in these cells (Figure 3.3). Additionally,
HEK-tau cells expressing HDAC6 with a non-functional second catalytic domain (H611A
mutant and H216AH611A) had acetylated tubulin levels comparable to wild-type control
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HEK-tau cells (Figure 3.3). As expected, targeting the α-tubulin deacetylase function of
HDAC6 led to an increase in acetylated tubulin.
Analysis of the phosphorylation status of tau was not confirmed in HEK-tau cells
stably expressing tau because HEK cells do not normally express tau therefore posttranslational modifications in these cells may not reflect the regulation of tau
homeostasis in neurons.

Further, only tau isoforms with four microtubule-binding

repeats without exon 2 and exon 3 are stably expressed in HEK-tau cells. Normal adult
human brain contains approximately a 1:1 ratio of the 3R tau and 4R tau isoforms and
deviation from this ratio has been associated with neurodegenerative disease (Andorfer
et al., 2003; Ballatore et al., 2007).

Further experiments to determine if increased

HDAC6 expression alters tau phosphorylation in an endogenous system were required
to address changes to tau pathology in neurons.

3.4 Methods
3.4.1
3.4.1.1

Cell culture
HEK-tau cells
HEK-tau cells (Dr. Gail V. W. Johnson, University of Rochester Medical Center)

were maintained in Dulbecco’s Minimum Essential Medium (DMEM) (Invitrogen,
Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS) at 37 °C with 5% CO2.
Cells were transfected at 70% confluency in t-25 flask 24 hrs after plating with
LipoD293 according to manufactures instructions (SignaGen).
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3.4.2

Constructs and site-directed mutagenesis of HDAC6
The cDNA of human HDAC6 was obtained from pcDNA3.1(+)HDAC6FLAG

(Addgene plasmid #13823) and used to create catalytically inactive HDAC6. Cysteine
mutants were prepared by site-directed mutagenesis of wild-type HDAC6 using
oligonucleotide primers to target the first catalytic domain (H216A), or the second
catalytic domain (H611A) under the following PCR profile: 1 cycle (95 °C for 1 min); 18
cycles (95 °C for 50 s, 68 °C for 50 s, 68 °C for 9.5 min); 1 cycle (68 °C for 7 min)
(Agilent Technologies, QuickChangeII XL Site-directed Mutagenesis kit #200521). The
catalytically inactive double mutant (H216AH611A) was created by creating a single
catalytic domain mutant and then targeting the remaining catalytic domain. Mutations
were confirmed by sequencing. The H216A primer was 5'-cattaggcctcctggacatgccgccca
gcac-3' and the H216A antisense primer was 3'-gtaatccggaggacctgtacggcgggtcgtg-5'.
The H611A primer was 5'-gtcccccaggacacgccgcagagcaggatg-3' and the H611A
antisense primer was 3'-cagggggtcctgtgcggcgtctcgtcctac-5'.

3.4.3

Cell lysis, immunoblotting and analysis
HEK-tau cells were collected in lysis buffer (50 mM Tris pH 7.4, 150 mM NaCl,

1% Triton X-100, 1 mM EDTA, 1 mM Na3VO4, 1 mM NaF, and Protease Inhibitor
Cocktail (Sigma P8340) containing 1.04 mM AEBSF, 15 µM Pepstatin A, 14 µM E-64, 2
µM Leupeptin, 4 µM Bestatin, 80 nM Aprotinin), incubated at 4 °C shaking for 30 minutes
and centrifuged at 4 °C at 12,000 g for 10 minutes.
determined by bicinchoninic (BCA) assay (Pierce).

Protein concentrations were

Total protein lysates (20 µg per

sample) were separated by SDS-PAGE, transferred to nitrocellulose membrane with
CAPS transfer buffer (10 mM 3-(cyclohexylamino)-1-propanesulfonic acid (CAPS), 10 %
Methanol, pH 11) and immunoblotted. The membrane was blocked with 5 % bovine
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serum albumin (BSA) in 1X Tris Tween Buffered Saline (1X TTBS; 20 mM Tris, 137 mM
NaCl, 0.1 % Tween-20, pH 7.6), and antibody incubations in 1 % BSA 1X TTBS and
washes with 1 % BSA 1X TTBS. The primary antibodies used in this study were: Mouse
Anti-Tau5 (Invitrogen #AHB0042), Mouse Anti-FLAG (Stratagene #200471), Mouse AntiPP1 E-9 (Santa Cruz, sc-7482), Mouse Anti-Acetylated Tubulin 6-11B-1 (Sigma, T6793.2ML), Rabbit Anti-GAPDH (Sigma, G9545-25UL). The secondary antibodies used in
this study were: Goat Anti-Mouse IgG, HRP (Millipore, AP308P), Goat Anti-Rabbit IgG,
HRP (Millipore, AP307P). The membranes were incubated with SuperSignal West Pico
Chemiluminescent Substrate (Pierce, 34080) and imaged on a G:box with cooled-CCD
camera (Syngene). HRP inactivation by excess hydrogen peroxide (blot incubation in 30
% H202 for 30 min shaking at 37 °C) was used to enable multiple membrane probing of
different species (rabbit vs. mouse) without the need for stripping blots. Signal from
GAPDH was used as a loading control for normalization. Signal from wild-type nontransfected HEK-tau cells were used as basis for the change in protein signal due to
increased expression of HDAC6. Band quantification was carried out using G:box gene
tools analysis software. All figures were prepared with GraphPad Prism ® version 6.
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4

CHAPTER 4

INCREASED HDAC6 EXPRESSION IS AN EARLY MARKER OF AD PROGRESSION

4.1 Introduction
A major hurdle in studying AD is identifying novel targets that alter disease
progression and pathology. Once it was established that HDAC6 could be a potential
underlying molecular factor altering tau pathology in a heterologuous expression system
experiments were designed to investigate the neuropathological role of HDAC6 in AD in
primary dissociated hippocampal neurons. The experiments described in this chapter
were performed to assess if increased HDAC6 protein levels in primary dissociated
hippocampal neurons leads to the missorting of pathological phosphorylated tau to the
soma and early synaptic dysfunction of these neurons. Primary dissociated neurons are
the simplest neuron culture system for evaluating changes in synaptic proteins and
neuronal function.

The hippocampus was chosen because of its prominent role in

learning and memory in the mammalian brain, the hippocampus is greatly decreased in
size in AD due to neuron death, and HDAC6 protein levels are increased by 91% in the
hippocampus of human post-mortem AD brains compared to age-matched control brains
(Ding et al., 2008; Thies et al., 2013).
Another major hurdle in developing a neuron cell culture model system to study
underlying molecular mechanisms in AD progression is that neurons are notoriously
difficult to deliver genes of interest to using standard mammalian gene delivery
techniques.

Neurons are post-mitotic and very sensitive to physical stress, and to

changes in temperature, pH and osmolarity (Karra and Dahm, 2010).

Calcium

phosphate (CaPO4) transfection results in low gene delivery (>5%), low expression, and
few viable transfected cells where as lipid based transfection methods (Lipofectamine)
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are toxic to neurons (Karra and Dahm, 2010). Additionally, CaPO4 transfections have
the highest gene delivery efficiency between day in vitro (DIV) 7 and DIV 10. After this
small-time frame, >1% of neurons are typically transfected. Alternatively, nucleofection
is a method similar to electroporation in that a series of high voltage pulses enable gene
delivery.

Nucleofection is a proprietary technique requiring expensive reagents and

equipment that have been modified for efficient (>60%) primary neuron gene delivery
(Lonza Amaxa Nucleofector™). Nucleofection requires very high concentrations of cells
and the gene of interest to be delivered to neurons while in suspension before plating at
DIV 0.

Methods that require gene delivery before DIV 16 have limited success in

evaluating changes in synaptic proteins and neuronal function if the transfected neurons
do not survive to DIV 18 to DIV 24 when they are synaptically active.
The only established technology to deliver genes of interest to neurons at any
age with high efficiency is recombinant DNA technology via recombinant virus.
Recombinant viruses are the method of choice for gene delivery in neurons because
gene delivery efficiency has been reported to achieve 90 to 99% transduction,
depending on the virus. Recombinant viruses are not the first choice in gene delivery for
neurons because they are a labor intensive, expensive, and demand safety precautions,
typically requiring biosafety level 2+ practices.

For these experiments, recombinant

adenovirus technology was chosen because the recombinant virus does not integrate
into the genome eliminating the risk of insertional mutagenesis and ease of cloning and
generating recombinant adenovirus (Karra and Dahm, 2010; Luo et al., 2007).
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4.2 Results
4.2.1

HDAC6 Gene Delivery in Neurons
Several methods were employed to deliver HDAC6 to primary neurons including

CaPO4, and nucleofection. Each of these methods were unsuccessful in transfecting
neurons after DIV 10. Each method resulted in less than 1% transfection efficiency and
transfected neurons overexpressing HDAC6 were found to not be viable 4 days posttransfection (data not shown).

A collaboration with Dr. Gregory Tew’s lab (UMASS

Amherst, Polymer Science and Engineering) was initiated to evaluate novel polymers in
mediating gene delivery in neurons.

These novel polymers had less than 1%

transfection efficiency, and were unsuccessful in transfecting neurons past DIV 10 (data
not shown).

In order to evaluate if increased HDAC6 protein levels in primary

dissociated hippocampal neurons is an underlying molecular factor that leads to the
missorting of pathological phosphorylated tau to the soma and early synaptic dysfunction
of these neurons, recombinant HDAC6-adenovirus was generated and used to deliver
FLAG-tagged HDAC6 to neurons.

Recombinant HDAC6_FLAG-Adenovirus (HFA)

infection resulted in robust gene expression and >70% transfection efficiency in neurons
at MOI 100. Representative widefield images taken at 40X magnification of neurons
infected at DIV 10 and fixed 36 hr post-transfection at DIV 12 show high transfection
efficiency and expression (Figure 4.1B). Fixed neuron cultures are autofluorescent and
as expected, control neurons show non-specific autofluorescence (Figure 4.1A).
Representative phase contrast images of wild-type control neurons vs. HFA infected
neurons show healthy cultures (Figure 4.1C, Figure 4.1D).

These experiments

established HFA infection as a reproducible and effective method for gene delivery of
flag-tagged HDAC6 to primary hippocampal neurons.
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Figure 4.1. Primary Hippocampal Neurons at DIV 12
Scale bars, 100µM
A) Autofluorescence of FLAG stained wild-type control neurons, DIV 12 at 40X.
B) Distribution HDAC6 expression of FLAG stained HFA infected neurons, 36 hr postinfection DIV 12 at 40X.
C) Phase contrast image of control neurons from A, DIV 12 at 40X.
D) Phase contrast image of HFA infected neurons from B, DIV 12 at 40X.
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4.2.2

HDAC6 Overexpression Missorts Total Tau, Early and Late Pathological
Tau to the Soma of Neurons 36 hr Post-Infection at DIV 12.
To assess if increased HDAC6 expression had an effect on tau localization,

primary hippocampal neurons containing immature synapses were infected with HFA at
an MOI of 100 and fixed 36 hrs post-infection at DIV 12. Established tau markers were
used to determine the effect of HDAC6 overexpression on the distribution of total tau, as
well as early and late pathological tau. The monoclonal Tau-5 antibody was used to
detect total tau (both phosphorylated and non-phosphorylated forms of tau) (Tau-5,
Invitrogen). The pTau231 antibody was used to detect phosphorylation at Threonine
231, a site important for regulating the ability of tau to bind microtubules and the
pTau202 antibody specific to phosphorylation at Serine 202 was used to detect tau
pathology in early and late stages of NFT formation (Andorfer et al., 2003).
In normal primary hippocampal neurons DIV 12 containing immature synapses,
tau has distinct puncta staining (Figure 4.2A). Within 36 hr of HDAC6 overexpression,
neurons infected with HFA, total tau appears in the entire neuron, axon and
somatodendritic compartment (Figure 4.2A). HDAC6 overexpression led to a shift in the
localization of total tau, a 1.7 fold increase of Tau-5 in soma of HDAC6 overexpressing
neurons vs. control neurons.
To assess if the missorted tau was phosphorylated, a phospho-specific antibody
(pTau231) that detects tau unbound from the microtubules was used. Within 36 hr of
HDAC6 overexpression, neurons infected with HFA, increased pTau231 immunostaining
appears in the entire neuron, axon and somatodendritic compartment whereas control
cells showed very little pTau231 immunostaining (Figure 4.3). HDAC6 overexpression
led to a increase in phosphorylated tau and a 1.39 fold increase in pTau231 in soma of
HDAC6 overexpressing neurons compared to control neurons.
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Next, a phospho-specific antibody (pTau202, phosphorylated Serine 202) that
detects early and late pathological tau was used to determine if missorted tau was in fact
NFTs. Within 36 hr of HDAC6 overexpression, neurons infected with HFA, increased
pTau202 immunostaining appears in the entire neuron, axon and somatodendritic
compartment whereas control cells have distinct puncta staining restricted from the
soma (Figure 4.4).

HDAC6 overexpression led to an increase in phosphorylated

pathological tau, a 1.4 fold increase in the accumulation of pathological tau in the soma
of

HDAC6

overexpressing

neurons

compared

to

control

neurons.

HDAC6

overexpression in primary hippocampal neurons containing immature synapses led to
the missorting of total tau, regulatory tau, and early and late pathological tau to the
somatodendritic compartment.
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Figure 4.2. Increased Tau-5 in Soma of Neurons Overexpressing HDAC6
A) Tau-5 distribution in wild-type control neurons (top) at DIV 12 and neurons
overexpressing HDAC6 (bottom) 36 hrs post-HFA MOI 100 infection at DIV 12. Scale
bars 100µM.
B) Quantification of Tau-5 fluorescence intensity in soma plotted as mean ± S.E.M.
Control, n = 143 cells (14 FOV); HDAC6 overexpressing, n = 109 cells (14 FOV). **** P
value < .0001. FOV= fields of view

71

#"

pTau231 fluorescence intensity (a.u.)

!"

!"#$%"&'
()*+,-.'

pTau231 in Soma
1500

***
1000

500

0

Control

Overexpressing HDAC6

/01'.22'
()*+,-.'
Figure 4.3. Increased pTau231 in Soma of Neurons Overexpressing HDAC6
A) pTau231 distribution in wild-type control neurons (top) at DIV 12 and neurons
overexpressing HDAC6 (bottom) 36 hrs post-HFA MOI 100 infection at DIV 12. Scale
bars 100µM.
B) Quantification of pTau231 fluorescence intensity in soma plotted as mean ± S.E.M.
Control, n = 146 cells (10 FOV); HDAC6 overexpressing, n = 150 cells (15 FOV). *** P
value = 0.0003. FOV= fields of view
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Figure 4.4. Increased pTau202 in Soma of Neurons Overexpressing HDAC6
A) Pathological pTau202 distribution in wild-type control neurons (top) at DIV 12 and
neurons overexpressing HDAC6 (bottom) 36 hrs post-HFA MOI 100 infection at DIV 12.
Scale bars 100µM.
B) Quantification of pTau202 fluorescence intensity in soma plotted as mean ± S.E.M.
Control, n = 195 cells (16 FOV); HDAC6 overexpressing, n = 139 cells (21 FOV). *** P
value = 0.0003. FOV = fields of view
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4.2.3

Increase in Pathological pTau202 in Soma of Synaptically Active HDAC6
Overexpressing Neurons.
To assess if HDAC6 overexpression had an effect on tau localization in

synaptically active neurons, primary hippocampal neurons containing mature synapses
were infected with HFA at an MOI of 100 at DIV 18 and fixed 36 hrs post-infection at DIV
20 and 72 hrs post-infection at DIV 21.

Within 36 hr of HDAC6 overexpression,

synaptically active neurons infected with HFA at DIV 20 have increased pTau202 in the
entire neuron, axon and somatodendritic compartment whereas control cells have
distinct tau puncta staining restricted from the soma (Figure 4.5A).

HDAC6

overexpression 36 hrs post-infection led to a 1.22 fold increase in the accumulation of
phosphorylated pathological tau in the soma of HDAC6 overexpressing neurons
compared to control neurons at DIV 20 (Figure 4.5B).

By 72 hrs of HDAC6

overexpression in synaptically active neurons at DIV 21 there is a distinct increase in the
accumulation of phosphorylated pathological tau in the soma and puncta whereas
control cells have tau puncta staining and tau restricted from the soma (Figure 4.6A).
Interestingly, HDAC6 overexpression 72 hrs post-infection led to a 1.33 fold increase in
the accumulation of phosphorylated pathological tau in the soma of HDAC6
overexpressing neurons compared to control neurons at DIV 21 (Figure 4.6B).
Comparison of pTau202 in the soma of control neurons at 36 hr vs. 72 hr was not
significantly different. There is an age-dependent 1.13 fold increase in the amount of
pTau202 accumulating in the soma of HDAC6 overexpressing neurons at 36 hr at DIV
20 vs. 72 hrs at DIV 21 and this increase is significant (P value = 0.0409).
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Figure 4.5. Increased pTau202 in Soma of Synaptically Active Neurons
Overexpressing HDAC6 36 hrs post-infection at DIV 20
A) Pathological pTau202 distribution in wild-type control neurons (top) at DIV 20 and
neurons overexpressing HDAC6 (bottom) 36 hrs post-HFA MOI 100 infection at DIV 20.
Max projection images of laser scanning confocal z-stacks, 63X oil-immersion, scale
bars 50µM.
B) Quantification of pTau202 fluorescence intensity in soma plotted as mean ± S.E.M.
Control, n = 113 cells (33 FOV); HDAC6 overexpressing, n = 114 cells (29 FOV). ** P
value = 0.0019.
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Figure 4.6. Increased pTau202 in Soma of Synaptically Active Neurons
Overexpressing HDAC6 72 hrs post-infection at DIV 21
A) Pathological pTau202 distribution in wild-type control neurons (top) at DIV 21 and
neurons overexpressing HDAC6 (bottom) 72 hrs post-HFA MOI 100 infection at DIV 21.
Max projection images of laser scanning confocal z-stacks, 63X oil-immersion, scale
bars 50µM.
B) Quantification of pTau202 fluorescence intensity in soma plotted as mean ± S.E.M.
Control, n = 146 cells (40 FOV); HDAC6 overexpressing, n = 140 cells (43 FOV). **** P
value < 0.0001.
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4.2.4

Decreased pTau202 Puncta in Synaptically Active HDAC6 Overexpressing
Neurons at DIV 20
To assess if HDAC6 overexpression had an effect on the size or number of tau

puncta in synaptically active neurons, primary hippocampal neurons containing mature
synapses were infected with HFA at an MOI of 100 at DIV 18 and fixed 36 hrs postinfection at DIV 20. Puncta size ranges are typically characterized into three size ranges
based on their role in synaptic plasticity: 0.2 – 0.5µM2, 0.5 – 1µM2, and 1 - 2µM2.
Analysis of the average pTau202 puncta overall size for control compared to HDAC6
overexpressing neurons at 36 hrs post-infection at DIV 20 was not significant (control =
0.612 ± 0.003, n=15,876; HDAC6 overexpressing = 0.621 ± 0.003, n=12,312). At 36 hr
post-infection, neurons overexpressing HDAC6 at DIV 20 had an overall decrease in
total number of puncta at each size range compared to wild-type control neurons at DIV
20 (Figure 4.7). Although this reduction in average number of pTau202 puncta per FOV
in each size range was not significant, the decrease in total number of puncta was
22.45% (total pTau202 puncta detected 0.2 to 2µM2: control = 15,876; HDAC6
overexpressing = 12,312).

Comparison of images of control neurons compared to

HDAC6 overexpressing neurons at 36 hr post-infection at DIV 20 show an increased
overall fluorescence intensity of pTau202 puncta (Figure 4.5A) but the size of pTau202
puncta was decreased at each size range, which led to investigation of the average
fluorescence intensity of the detected puncta at each size range. Indeed, at each size
range the fluorescence intensity of pTau202 puncta was significantly increased in
neurons overexpressing HDAC6 at 36 hr post-infection at DIV 20 vs. control neurons
(Figure 4.8).
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Figure 4.7. Average Number of pTau202 Puncta per FOV at DIV 20
The wild-type control neuron data was from 113 cells (33 FOV) at DIV 20. HDAC6
overexpressing neuron 36 hrs post-infection at DIV 20 data was from 114 cells (29
FOV). The total number of pTau202 puncta detected (0.2 to 2µM2) from 113 control
cells= 15,876; 114 HDAC6 overexpressing cells = 12,312.
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Figure 4.8. Average Fluorescence Intensity of pTau202 puncta in DIV 20 neurons
The wild-type control neuron data was from 113 cells (33 FOV) at DIV 20. HDAC6
overexpressing neuron 36 hrs post-infection at DIV 20 data was from 114 cells (29
FOV). Data plotted as mean ± SEM, n = total puncta detected. At 0.2 to 0.5µM2: Control
= 2,536 ± 2.941, n=8,426; HDAC6 = 2,574 ± 3.750, n=6,521. At 0.5 to 1µM2: Control =
2,732 ± 4.386, n=4,873; HDAC6 = 2,768 ± 5.533, n=3,664. At 1 to 2µM2: Control =
2,844 ± 6.059, n=2,577; HDAC6 = 2,867 ± 6.886, n=2,127.
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4.2.5

Decreased pTau202 Puncta in Synaptically Active HDAC6 Overexpressing
Neurons at DIV 21
Next, to assess if HDAC6 overexpression had an effect on the size or number of

tau puncta in synaptically active neurons, primary hippocampal neurons containing
mature synapses were infected with HFA at an MOI of 100 at DIV 18 and fixed 72 hrs
post-infection at DIV 21. Analysis of the average size of pTau202 puncta for control vs.
HDAC6 overexpressing neurons at 72 hrs post-infection at DIV 21 was significant
(control = 0.596 ± 0.002, n=31,156; HDAC6 overexpressing = 0.607 ± 0.003, n=16,884).
At 72 hr post-infection, neurons overexpressing HDAC6 at DIV 21 had a decrease in
total number of puncta at each size range compared to wild-type control neurons at DIV
21 (Figure 4.9). The decrease in total number of pTau202 puncta was 45.8% (total
pTau202 puncta detected 0.2 to 2µM2: control = 31,156; HDAC6 overexpressing =
16,884). Images of control neurons compared to HDAC6 overexpressing neurons at 72
hr post-infection at DIV 21 appeared to have increased overall fluorescence intensity of
pTau202 puncta (Figure 4.6A) but the actual size of pTau202 puncta was decreased at
each size range, which led to investigation of the average fluorescence intensity of the
detected puncta at each size range.

Indeed, at each size range the fluorescence

intensity of pTau202 puncta was increased and statistically significant in neurons
overexpressing HDAC6 at 72 hr post-infection at DIV 21 compared to control neurons
(Figure 4.10).
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Figure 4.9. Average Number of pTau202 Puncta per FOV at DIV 21
The wild-type control neuron data was from 146 cells (40 FOV) at DIV 21. HDAC6
overexpressing neuron 72 hrs post-infection at DIV 21 data was from 140 cells (43
FOV). The number of total pTau202 puncta detected (0.2 to 2µM2) from 146 control cells
= 31,156; 140 HDAC6 overexpressing cells = 16,884. Data plotted as mean ± SEM, n =
total FOV. At 0.2 to 0.5µM2: Control = 432.6 ± 34.83, n=40; HDAC6 = 212.4 ± 20.69,
n=43. At 0.5 to 1µM2: Control = 225.7 ± 19.55, n=40; HDAC6 = 116.9 ± 11.85, n=43. At
1 to 2µM2: Control = 120.6 ± 11.62, n=40; HDAC6 = 63.12 ± 7.273, n=43.
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Figure 4.10. Average Fluorescence Intensity of pTau202 puncta in DIV 21 neurons
The wild-type control neuron data was from 146 cells (40 FOV) at DIV 21 and HDAC6
overexpressing neuron 72 hrs post-infection at DIV 21 data was from 140 cells (43
FOV). Data plotted as mean ± SEM, n = total puncta detected. At 0.2 to 0.5µM2: Control
= 2,570 ± 2.132, n=17,304; HDAC6 = 2,600 ± 3.356, n=9,128. At 0.5 to 1µM2: Control =
2,744 ± 3.158, n=9,029; HDAC6 = 2,796 ± 4.837, n=5,028. At 1 to 2µM2: Control =
2,822 ± 4.135, n=4,823; HDAC6 = 2,875 ± 6.295, n=2,714.
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4.2.6

Decreased PSD-95 Puncta in Synaptically Active Neurons Overexpressing
HDAC6
To assess if HDAC6 overexpression had an effect on the size or number of PSD-

95 puncta in synaptically active neurons, primary hippocampal neurons containing
mature synapses were infected with HFA at an MOI of 100 at DIV 18 and fixed at 36 hr
post-infection at DIV 20 and 72 hrs post-infection at DIV 21. PSD-95 is an important
scaffolding protein that has a functional role in maintaining molecular organization of
postsynaptic dendritic spines and synaptic plasticity. Significant reduction of PSD-95 is
an indicator of synaptic dysfunction in post-mortem AD brains (Proctor et al., 2011)
therefore PSD-95 was used as a marker for synaptic dysfunction in neurons
overexpressing HDAC6.
Representative images of PSD-95 puncta from DIV 20 for control and HDAC6
overexpressing at 36 hr post-infection neurons are shown in Figure 4.11A.
Quantification of PSD-95 puncta from DIV 20 for control compared to HDAC6
overexpressing at 36 hr post-infection revealed neurons overexpressing HDAC6 at DIV
20 had significant decreases in total number of puncta at each size range compared to
wild-type control neurons at DIV 20 (Figure 4.11).

Within 36 hrs of HDAC6

overexpression the average PSD-95 puncta size (0.2 to 2µM2) from DIV 20 neurons
decreased by 1.15 fold compared to wild-type control neurons (Figure 4.12).

The

percent decrease of the total number of PSD-95 puncta was 77.9% (total pTau202
puncta detected 0.2 to 2µM2: control = 2,697; HDAC6 overexpressing = 596).
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Figure 4.11. Average Number of PSD-95 Puncta per FOV at DIV 20
The wild-type control neuron data was from 113 cells (33 FOV) at DIV 20. HDAC6
overexpressing neuron 36 hrs post-infection at DIV 20 data was from 114 cells (29
FOV).
A) Representative PSD-95 images showing puncta distribution in control neurons (top)
at DIV 20 and neurons overexpressing HDAC6 infected with HFA MOI 100 (bottom) and
fixed at 36 hrs post-infection at DIV 20. Max projection images of laser scanning
confocal z-stacks, 63X oil-immersion, scale bars 50µM.
B) Data plotted as mean ± SEM, n = total FOV. At 0.2 to 0.5µM2: Control = 55.21 ±
8.285, n=33; HDAC6 = 15.97 ± 3.814, n=29. At 0.5 to 1µM2: Control = 20.33 ± 3.624,
n=33; HDAC6 = 3.586 ± 0.9023, n=29. At 1 to 2µM2: Control = 6.152 ± 1.501, n=33;
HDAC6 = 1.000 ± 0.5012, n=29. The total number pTau202 puncta detected (0.2 to
2µM2) from 113 control cells= 2,697; 114 HDAC6 overexpressing cells = 596.
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Figure 4.12. Average Size of PSD-95 Puncta from DIV 20 Neurons
The wild-type control neuron data was from 113 cells (33 FOV) at DIV 20. HDAC6
overexpressing neuron 36 hrs post-infection at DIV 20 data was from 114 cells (29
FOV).
Data plotted as mean ± SEM, n = total number puncta: Control = 0.483 ± 0.006,
n=2,697; HDAC6 overexpressing = 0.418 ± 0.011, n=596.

85

Next, analysis of the effect of HDAC6 overexpression 72 hrs post-infection of DIV
21 on PSD-95 puncta number and size from primary hippocampal neurons with mature
synapses was compared to wild-type control DIV 21 neurons. Representative images of
PSD-95 puncta from DIV 21 for control vs. HDAC6 overexpressing at 72 hr postinfection neurons are shown in Figure 4.13A. Quantification of PSD-95 puncta from DIV
21 for control and HDAC6 overexpressing at 72 hr post-infection revealed neurons
overexpressing HDAC6 at DIV 21 had significant decreases in total number of puncta at
both 0.2 – 0.5µM2 and 0.5 – 1µM2 ranges compared to wild-type control neurons at DIV
21 (Figure 4.13B). The percent decrease of the total number of PSD-95 puncta was
53.44% (total pTau202 puncta detected 0.2 to 2µM2: control = 3,052; HDAC6
overexpressing = 1,421). Analysis of the average PSD-95 puncta size (0.2 to 2µM2) for
HDAC6 overexpressing neurons at 72 hrs post-infection at DIV 21 increased slightly by
1.08 fold compared to wild-type control neurons DIV 21 (Figure 4.14).

86

#"

!"
72hr average PSD-95 puncta per FOV

!"#$%"&'
()*+,-'

average number puncta

80

Control, n = 146 cells
HDAC6, n = 140 cells

60
40

** P value = 0.0021
* P value = 0.0266

**

20

*

ns

0

0.2 - 0.5

0.5 - 1

1-2

surface area !m2

./0'122'
345%'6#7'
()*+,-'
Figure 4.13. Average Number of PSD-95 Puncta per FOV at DIV 21
The wild-type control neuron data was from 146 cells (40 FOV) at DIV 21. HDAC6
overexpressing neuron 72 hrs post-infection at DIV 21 data was from 140 cells (43
FOV). A) Representative PSD-95 images showing puncta distribution in control neurons
(top) at DIV 21 and neurons overexpressing HDAC6 infected with HFA MOI 100
(bottom) and fixed at 72 hrs post-infection at DIV 21. Max projection images of laser
scanning confocal z-stacks, 63X oil-immersion, scale bars 50µM.
B) Data plotted as mean ± SEM, n = total FOV. At 0.2 to 0.5µM2: Control = 53.83 ±
9.032, n=40; HDAC6 = 21.72 ± 4.217, n=43. At 0.5 to 1µM2: Control = 17.28 ± 3.175,
n=40; HDAC6 = 8.302 ± 2.376, n=43. At 1 to 2µM2: Control = 5.200 ± 1.133, n=40;
HDAC6 = 3.023 ± 0.973, n=43. The total number pTau202 puncta detected (0.2 to 2µM2)
from 146 control cells= 3,052; 140 HDAC6 overexpressing cells = 1,421.

87

72hr average PSD-95 puncta size

surface area !m2

0.6

***

Control, n = 146 cells
HDAC6, n = 140 cells

0.4

*** P value = 0.0009
0.2

C
A
D
H

C

on

tr

ol

6

0.0

Figure 4.14. Average Size of PSD-95 Puncta from DIV 21 Neurons
The wild-type control neuron data was from 146 cells (40 FOV) at DIV 21. HDAC6
overexpressing neuron 72 hrs post-infection at DIV 21 data was from 140 cells (43
FOV). Data plotted as mean ± SEM, n = total number puncta: Control = 0.465 ± 0.005,
n=3,052; HDAC6 overexpressing = 0.500 ± 0.009, n=1,421.
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4.3 Discussion
Tau homeostasis is regulated by a series of post-translational modifications
including phosphorylation, acetylation, glycosylation, etc (Spires-Jones et al., 2009). It is
well established that tau is a microtubule-associated protein primarily expressed in
neurons and localized to the axon (Ballatore et al., 2007; Iqbal et al., 2005; Johnson and
Stoothoff, 2004). This study focused solely on changes in tau phosphorylation because
of its implicated role in tau dysregulation, AD pathology, and disease progression.
Phosphorylation of tau is a post-translational modification that regulates the
affinity of tau for microtubules. In healthy neurons, the phosphorylation of tau is tightly
regulated enabling tau to bind to microtubules stabilizing them whereas and
phosphorylated tau with reduced affinity for microtubules enables axonal transport. Sitespecific phosphorylation of tau enables tau to regulate cytoskeletal microtubule
dynamics, axonal transport and neurite outgrowth (Johnson and Stoothoff, 2004).
Specifically, phosphorylation of tau at threonine 231 has been observed to reduce the
affinity of tau for microtubules (Cho and Johnson, 2003; Cho and Johnson, 2004;
Goedert et al., 1994). However, phosphorylation alone is not an indicator of AD tau
pathology as healthy fetal and adult brains have phosphorylated tau (Buee et al., 2000).
Abnormal hyperphosphorylation that leads to tau aggregation and missorting is
an indicator of tau pathology. In degenerating neurons, hyperphosphorylation of tau
leads to intracellular tau aggregation and the formation of neurofibrillary tangles (NFTs)
containing both hyperphosphorylated and non-phosphorylated tau isoforms that are
missorted to the somatodendritic compartment. Interestingly, the largest tau isoform has
seventy-nine threonine and serine residues that are potential phosphorylation sites
(Buee et al., 2000) of which more than half have been found to be phosphorylated and
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implicated in tau pathology in AD brains (Hanger et al., 2007).

Tau dysregulation,

mislocalization of tau to soma and dendritic spines, the role of tau in dendritic spines,
and tau dysfunction are implicated in AD pathology and progression (Haass and
Mandelkow, 2010; Hoover et al., 2010; Ittner et al., 2010). Both missorting of tau and
synapse loss is an early change in AD brains that precedes Aβ accumulation, NFTs and
cognitive dysfunction.
HDAC6 recombinant adenovirus was developed to deliver HDAC6 to primary
dissociated hippocampal neurons isolated from post-natal rat brains for the investigation
of the neuroprotective vs. neuropatholgoical role of increased HDAC6 protein levels in
AD pathology and synaptic dysfunction. Early changes that mediate tau dysregulation
and the accumulation and missorting of hyperphosphorylated pathological tau have
remained elusive, therefore initial experiments were designed to investigate if HDAC6
overexpression led to any change in tau pathology including phosphorylation and
missorting to the somatodendritic compartment in developing neurons.

The data

presented here indicates that HDAC6 as an underlying molecular factor in AD and a key
player in mediating the missorting of pathological tau and synaptic dysfunction.
HDAC6_FLAG-Adenovirus enabled reproducible, efficient HDAC6 gene delivery
and subsequent overexpression in primary dissociated hippocampal neurons (Figure
4.1).

Increased expression of HDAC6 resulted in AD tau pathology and synaptic

dysfunction. Increased HDAC6 was neuropathological in primary hippocampal neurons.
HDAC6 overexpression missorted total tau to the soma of developing neurons (Figure
4.2).

Since NFTs are composed of aggregates of phosphorylated and non-

phosphorylated forms of tau that missort to the soma of neurons markers to determine
the phosphorylation state of missorted tau was used. The phospho-specific antibody
pTau231 detects tau with disrupted affinity for microtubules. Wild-type control neurons

90

had minimal staining of pTau231 suggesting these neurons have stable microtubules
(Figure 4.3).

Neurons overexpressing HDAC6 had distinct pTau231 staining of the

entire neuron, axon and somatodendritic compartment suggesting a potentially
destabilized microtubule network. Disruption of the microtubule network is a central
mechanism leading to neuronal dysfunction (Zhang et al., 2013).
Further, the pTau202 antibody that detects phosphorylated Serine 202 indicative
of NFTs (aggregated hyperphosphorylated tau) was used to confirm early and late tau
pathology.

Surprisingly, wild-type control neurons stained with pTau202 had puncta

staining restricted from the soma suggesting phosphorylation of Serine 202 may have a
functional role in mediating synaptic organization in healthy developing neurons (Figure
4.4). Neurons overexpressing HDAC6 show elevated pTau202 staining in the soma,
indicating pathological tau accumulation in the soma (Figure 4.4).

Dysfunction of

hyperphosphorylated tau is well-studied and implicated in microtubule destabilization,
aggregation, missorting of tau to the soma and dendritic spines, and synaptic
dysfunction in neurons.
Experiments in synaptically active neurons were performed to investigate the
impact of HDAC6 overexpression on tau pathology and synaptic dysfunction.

Tau

mislocalization in dendritic spines has been implicated in disrupting glutamate receptor
(AMPA and NMDA receptors) trafficking and hence synaptic function (Hoover et al.,
2010).

The phosphospecific antibody pTau202 was used to recognize aggregated

phosphorylated tau.

Synaptically active neurons overexpressing HDAC6 show

increased pTau202 staining in the soma, indicating pathological tau accumulation in the
soma compared to wild-type control neurons (Figure 4.5, Figure 4.6).

Synaptically

active, wild-type control neurons showed puncta staining of phosphorylated tau
restricted from the soma suggesting phosphorylation of Serine 202 may have a
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functional role in mediating synaptic organization in healthy synaptically active neurons
(Figure 4.5, Figure 4.6).

Additionally, synaptically active neurons overexpressing

HDAC6 had decreased total number of phosphorylated tau puncta suggesting changes
in synaptic organization in these neurons (Figure 4.7, Figure 4.9).
Missorting of tau to soma in neurons correlates with the degeneration of
synapses (Thies and Mandelkow, 2007), therefore I investigated changes in the size,
number and fluorescence intensity of tau puncta to determine potential synaptic
regulation mediated by HDAC6 expression. Compared to age-matched wild-type control
neurons, neurons overexpressing HDAC6 had decreased tau puncta. Interestingly, the
fluorescence intensity of size-matched tau puncta was increased in neurons
overexpressing HDAC6 indicating increases in the amount of phosphorylated tau protein
in puncta of the same size compared to wild-type neurons. This change in fluorescence
intensity of phosphorylated tau suggests increased pathological tau in puncta leads to
disruption of synaptic puncta organization and tau missorting in neurons overexpressing
HDAC6.
The shift in tau homeostasis that mediates functional tau and pathological tau is
regulated by a series of post-translational modifications. Recently, a number of studies
have implicated acetylated tau as contributing to tau dysfunction, aggregation and
accumulation by prevention of its degradation in AD (Cohen et al., 2011; Irwin et al.,
2012; Min et al., 2010). It is likely that a combination of post-translational modifications
(i.e. phosphorylation, acetylation) lead to hyperphosphorylated tau and accumulation of
aggregated tau that is missorted to soma of neurons.
Altered neuronal communication at the synapse and a decreased number of
postsynaptic receptors correlates with changes in synaptic strength and plasticity (Bingol
et al 2011). Experiments were designed to investigate any changes in the synaptic
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organization of an important scaffolding protein, postsynaptic density protein 95 (PSD95) mediated by HDAC6 overexpression.

PSD-95 is the most-abundant scaffolding

protein in postsynaptic densities, and is one of the most stable proteins in dendritic
spines (Chen et al., 2011; Kasai et al., 2010).

PSD-95 plays a functional role in

maintaining molecular organization of excitatory dendritic spines and plays a pivotal role
in LTD (Bhattacharyya et al., 2009; Chen et al., 2011). Interestingly, synaptically active
neurons overexpressing HDAC6 had significant decreases in the total amount of PSD95 puncta compared to wild-type control neurons (Figure 4.11, Figure 4.13). These
reductions in the total number of PSD-95 puncta in neurons overexpressing HDAC6
suggest HDAC6 has a neuropathological role in disrupting the molecular organization of
dendritic spines and impairing synaptic neurotransmission.

Additionally, loss of

postsynaptic scaffolding protein PSD is believed to contribute to AMPA receptor
dependent LTP deficits in AD (Proctor et al., 2011). The size of synaptic puncta has
been reported to correlate with changes synaptic neurotransmission and LTD and LTP.
The average size of PSD-95 puncta was reduced at 36 hr post-infection in neurons
overexpressing HDAC6 at DIV 20 (Figure 4.12), yet at neurons overexpressing HDAC6
for 72 hrs at DIV 21 the average size of PSD-95 puncta was increased (Figure 4.13).
The PSD-95 data of neurons overexpressing HDAC6 for 36 hrs and 72 hrs compared to
age-matched wild-type control neurons suggests a potential compensatory mechanism
altering the total number of PSD-95 puncta and average size of PSD-95 when synaptic
communication is disrupted by tau missorting and changes to PSD-95 during disease
progression.
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4.4 Methods
4.4.1
4.4.1.1

Cell Culture
HEK293T cells
HEK293T cells were maintained in Dulbecco’s Minimum Essential Medium

(DMEM) (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS) at
37°C and 5% CO2. Cells were plated at 70% confluency in T75-flask and transfected 24
hrs after plating with LipoD293 according to manufactures instructions (SignaGen).

4.4.1.2

HeLa cells
HeLa cells were maintained in Eagle's Minimum Essential Medium (EMEM)

(ATCC Catalog #30-2003) supplemented with 10% FBS at 37°C and 5% CO2.

For

Adenoviral titer, cells were plated at 85% confluency.

4.4.1.3

Dissociated hippocampal neurons
All experiments involving rats were performed in accordance with local

institutional and government regulation for animal welfare. Primary cultures of post-natal
rat hippocampal neurons isolated from Sprague-Dawley rat pups (Charles Rivers
Laboratories) were performed using standard procedures. Neurons were plated at 62–
75 × 103 cells/cm2 on poly-L-lysine coated glass coverslips and were grown in minimum
essential medium (MEM) containing 5% FBS, 25 mM glucose, B27 (Invitrogen), 2 mM
glutamine and Mito+ Serum Extender (BD Biosciences). Neurons were maintained in
culture with ½ media changes every three days.

Gene delivery was performed by

HDAC6_FLAG-Adenovirus at a 100-fold multiplicity of infection (MOI).
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4.4.2

Generation of HDAC6 recombinant adenovirus
Recombinant adenovirus was generated following the AdEasy method for

generation and production similarly to previously described (Luo et al., 2007). Briefly,
the following plasmids were used pcDNA3.1(+)HDAC6FLAG (Addgene plasmid
#13823),

pShuttleCMV (Addgene plasmid #16403), pAdEasy-1 (Addgene plasmid

#16400). The cDNA of human HDAC6 with an engineered c-terminal FLAG tag was
PCR amplified from pcDNA3.1(+)HDAC6FLAG subcloned into pShuttleCMV using 5’
BglII and 3’ HindIII sites. The resulting pShuttleCMV_HDAC6FLAG construct was
linearized with PmeI and co-transformed with pAdEasy-1 into Escherichia coli BJ5183
cells (Addgene strain # 16398) for homologous recombination. Recombinant adenoviral
plasmids were verified by PacI digestion. The recombinant adenoviral plasmid isolated
from verified recombinant clones was transformed into recombination-defective
Novablue strain. The recombinant adenoviral plasmid was then digested with PacI and
used to transfect HEK293T cells (which contain E1 genes for adenoviral packaging)
using LipoD293.

Media was changed 16 hours post-transfection following BSL-2+

practices, and cells were maintained at 37°C and 5% CO2 for 42 days until the primary
HDAC6_FLAG-adenoviral stock was harvested by freeze-thaw.

4.4.3

Recombinant Adenovirus titer using immunocytochemistry
HeLa cells were infected with crude HDAC6_FLAG-Adenoviral stocks titrated

from 10-5 to 10-16 in biological replicates of 4.
paraformaldehyde 24 hrs post-infection.

Cells were fixed with 4%

Fixed cells were permeabilized with 0.1%

TritonX-100. Cells were blocked with 5% goat serum and immunostained with a 1°
antibody that detects Adenovirus type 5 Hexon protein (DSHB catalog # TC31-9C12.C9)
followed by 2° Goat Anti-mouse IgG Dylight 488 (Pierce #35502). Widefield fluorescent
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images were acquired and the average number of infected cells per area was calculated.
The equation used to calculate viral titer was {(average number of infected cells/fields of
view)*(total number of fields of view possible/well)*(dilution factor)}/{(virus volume added
per well)}. This equation calculated the number of viral infection units per mL in the
crude viral stock. This method for adenovirus viral titer was designed with adenovirus
expert Dr. Gary Ketner at John Hopkins University School of Medicine by adapting a
protocol from his laboratory.

4.4.4 Neuron Immunocytochemistry
Neurons were fixed with 4% paraformaldehyde at the appropriate time-point.
Fixed cells were permeabilized with 0.1% TritonX-100. Cells were blocked with 5% goat
serum and immunostained with the appropriate primary and secondary antibodies. The
primary antibodies used were Mouse Anti-PSD-95 (Millipore #MAB1596), Mouse AntiTau5 (Invitrogen #AHB0042), Mouse Anti-FLAG (Stratagene #200471), Rabbit AntipTau202 (Anaspec #28017-025), Rabbit Anti-pTau231 (Anaspec #55313-025), Chicken
Anti-FLAG (AFLAG-5).

The secondary antibodies used were Goat Anti-mouse IgG

Dylight 488 (Pierce #35502), Goat Anti-rabbit IgG Dylight 549 (Pierce #35557), Goat
Anti-Chicken Alexa Fluor 633 (Invitrogen #A21103). Images were acquired using a Zeis
Laser Scanning 510 Meta confocal microscope at 63X (Plan-Apochromat 63X/1.4NA)
oil-immersion using the appropriate lasers (488nm, 543nm, 633nm) and filters. Four
channel (488nm, 549nm, 633nm, DIC) Z-stack 12 bit (1024 X 1024) images were
acquired as 26 stacks at .1µM intervals. Images were acquired with settings to avoid
pixel saturation and these settings were the same for all image acquisition for control
and HDAC6 overexpressing cells.
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4.4.4
4.4.4.1

Neuron Image analysis
FLAG Analysis
Images of at least 10 fields of view were taken for both control and HFA infected

neurons. Using ImageJ software (NIH), z-stacks images split into 4 channels and MAXintensity projection images of the appropriate channel were used. All neuron somas in
these images were chosen as region of interest (ROI), and three background areas were
chosen as background ROI for each image. The background ROI were averaged and
subtracted from the average FLAG fluorescence of the soma ROI.

Neurons were

identified as HDAC6 overexpressing neurons or positive infected cells if they had FLAG
fluorescence above the average control FLAG autofluorescence.

4.4.4.2

Tau Soma Analysis
Images of at least 10 fields of view were taken for both control and HFA infected

neurons. Using ImageJ software (NIH), z-stacks images were split into 4 channels and
MAX-intensity projection images of the appropriate channel were used.

All neuron

somas in these images were chosen as a ROI, and three background areas were
chosen as background ROI for each image. The background ROI were averaged and
subtracted from the average Tau fluorescence of the soma ROI.
prepared with GraphPad Prism ® version 6.
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All figures were

4.4.4.3

Tau puncta analysis
Images of at least 10 fields of view were taken for both control and HFA infected

neurons. Using ImageJ software (NIH), z-stacks images were split into 4 channels and
MAX-intensity projection images of the appropriate channel were used. To determine
Tau puncta size or the fluorescence intensity of puncta, images were analyzed using the
‘background subtracted’ function followed by ‘3D object counter’ function using a
threshold of 2000. The threshold value was determined manually and then applied to all
images, tau fluorescence detected was at least 5X above background. The object maps
containing the coordinates of detected objects were saved and manually verified. The
output data was also saved and then compiled for all FOV analyzed. All figures were
prepared with GraphPad Prism ® version 6.

4.4.4.4

PSD-95 puncta analysis
Images of at least 10 fields of view were taken for both control and HFA infected

neurons. Using ImageJ software (NIH), z-stacks images were split into 4 channels and
MAX-intensity projection images of the appropriate channel were used. To determine
PSD puncta size, images were analyzed using the ‘background subtracted’ function
followed by ‘3D object counter’ function using a threshold of 1700. The threshold value
was determined manually and then applied to all images, this allowed PSD-95
fluorescence detected to be at least 5X above background. The object maps containing
the coordinates of detected objects were saved and manually verified. The output data
was also saved and then compiled for all FOV analyzed. All figures were prepared with
GraphPad Prism ® version 6.
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5

CHAPTER 5

CONCLUSIONS AND FUTURE DIRECTIONS

5.1 Conclusions
The mammalian brain is complex and progress in the field is limited by the
availability of tools to probe the underlying molecular basis of synaptic communication
and dysfunction. The cell culture models used throughout this dissertation have both
advantages and disadvantages.

Heterologous expression systems offer the most

simplistic system to investigate and modulate synaptic communication.

Dissociated

primary hippocampal neuron culture allows for investigation and modulation of synaptic
communication in a simplified system compared to intact brain slice cultures whereas
slice cultures are a simplified system compared to animal models. Data generated from
any of these model systems need to be validated against knowledge generated from
human brain tissue to ensure global conclusions are representative of synaptic
communication and dysfunction in the human brain.
In this dissertation, I have investigated neuronal communication using novel
molecules to photocontrol receptors at the synapse, and identified HDAC6 as an
underlying molecular factor in Alzheimer’s disease (AD) tau pathology and synaptic
dysfunction.

This research has used techniques in chemical neurobiology, and

molecular and cellular biology including patch-clamp electrophysiology, immunoblotting,
and confocal microscopy. By employing these techniques I have answered questions
about the function of inhibitory receptor subtypes at synapses, and the role of HDAC6 in
AD in both heterologous expression systems and primary hippocampal neurons. This
research has given insight on the underlying molecular mechanisms of learning and
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memory by deciphering the role of receptor subtypes in synaptic communication, and
changes that indicate early synaptic dysfunction in AD.
I have described how we have successfully developed a series of LiGABAAR that
enable light-controlled inhibitory neurotransmission of subtype specific GABA receptors.
Specifically, we developed α1- and α5-LiGABAARs.

These LiGABAARs enabled

spatiotemporal precision control of ion channels at the synapse thus allowing us to
investigate the underlying mechanisms of subtype-specific neural inhibition. The PTLs
we developed enabled a method for photocontrolling engineered GABAA receptors that
was fast, reversible photoregulation, and subtype-specific. Our experiments revealed
that tethered muscimol acts as an antagonist to engineered GABAA receptors when
irradiated with 500 nm light.

This method enabled photoregulation of endogenous

mIPSCs from dissociated hippocampal neurons expressing LiGABAAR.

Further, this

method also enabled the photocontrol of action potential firing of intact brain slices.
I have used an in vitro heterologous cell culture system to investigate the
outcome of the overexpression of HDAC6 on tau and protein levels in HEK-tau cells.
The data from this study suggest that an increase in HDAC6 expression leads to
increased pathological tau accumulation and may be the result of decreased PP1 levels
in cells overexpressing HDAC6. Further, the expression of catalytically inactive HDAC6
in HEK-tau cells did not prevent the accumulation of increased pathological tau or the
decrease in PP1 levels. This data suggests that HDAC6 is a underlying molecular factor
altering both tau and PP1 protein levels, which may contribute to AD progression. I also
verified that HEK-tau cells overexpressing HDAC6 with a catalytically inactive second
deacetylase domain were in fact catalytically inactive by using a known substrate
acetylated tubulin as a reporter of cytosolic functional HDAC6. As expected, HDAC6
with catalytically inactive second deacetylase domain were unable to deacetylate tubulin.
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Additionally, this study revealed that the expression of tau does not inhibit the
deacetylase function of cells overexpressing catalytically active HDAC6.
Studies using dissociated primary hippocampal neurons were used to further
investigate the potential underlying molecular role of HDAC6 in altering key proteins
involved in AD progression. For this project, I designed and developed recombinant
HDAC6 adenovirus for efficient and reproducible HDAC6 gene delivery in neurons. This
method resulted in the development of a primary hippocampal neuron cell culture model
to study hallmarks of AD progression. The results presented in this dissertation reveal
increased expression of HDAC6 in dissociated primary hippocampal neurons as an
underlying molecular factor that contributes to the pathological missorting of
phosphorylated tau to the soma of affected neurons, reduction of tau puncta, and
reduction in PSD-95 puncta. These changes suggest that increased HDAC6 in neurons
leads to changes in the molecular organization of dendritic spines that suggest HDAC6
is involved in regulating changes in excitatory neurotransmission and LTD. The results
from

these

experiments

suggest

dissociated

primary

hippocampal

neurons

overexpressing HDAC6 can be used as a tissue culture model system to study changes
correlate with human AD progression and pathology.

5.2 Future Directions
Using the PTL approach, we developed a series of LiGABAARs. This technology
enables investigation into the roles that receptor subtypes play in mediating and altering
synaptic neurotransmission. Additional studies with these LiGABAARs provide a method
for precise, reversible photocontrol of sub-type specific receptors to investigate their
distribution, and examine their functional role in leaning and memory.

By exerting

photoswitchable control on engineered receptor subtypes in brain slices, we can
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investigate the role specific subtypes of GABAA receptors in intact brain tissue have in
preventing epilepsy.

Further, the PTLs we developed can be employed to exert

photocontrol on future engineered GABAA receptor subtypes of interest. Additionally,
‘knock-in’ mice expressing LiGABAARs in place of endogenous subunits could be used
to study genetically engineered receptors in the absence of wild-type background. The
photocontrol of GABA receptor study presented in this dissertation begins to address
how receptor subtypes contribute to inhibitory synaptic neurotransmission.

The

suggested future studies would enable further investigation into the role of receptor
subtypes have in synaptic communication. This knowledge would further the current
understanding of the molecular basis of learning and memory.
Alzheimer’s disease is a complex, multifactoral, slow progressing disease with no
cure and little understanding of the underlying molecular basis leading to the
pathological hallmarks of AD and synaptic dysfunction. By using a cell culture model, I
was able to investigate the neuropathological role of HDAC6 and underlying molecular
contributions that HDAC6 overexpression appears to have in AD tau pathology and
synaptic dysfunction. The main advantages of this system are a single gene is altered
enabling fast, efficient and reproducible pathological hallmarks representative of
changes in post-mortem AD brains and animal models. Further studies that investigate
early synaptic changes such as decreases in excitatory receptors (AMPA and NMDA)
are possible using dissociated hippocampal neurons overexpressing HDAC6. Future
studies using this system can investigate early changes that lead to defects in protein
degradation and the subsequent accumulation of aggregated proteins. Additionally, this
system can potentially be used for a high-throughput drug screen to determine if
targeting HDAC6 reverses or slows the progression of AD tau pathology and synaptic
dysfunction. Alternatively, this system can potentially be used for a high-throughput drug
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screens to determine if targeting kinases upregulated in AD will reverse or slows the
progression of AD tau pathology and synaptic dysfunction.

The investigation and

identification of increased HDAC6 expression as having an underlying neuropathological
role in AD tau pathology and synaptic dysfunction presented in this dissertation begins to
investigate early changes in AD that potentially could be targeted to prevent disease
progression. The suggested future studies would enable further investigation of early
changes in AD that may be the result of increased protein levels of HDAC6.
Investigation of early synaptic changes that contribute to memory and cognitive
impairment will greatly advancing our understanding of AD progression.
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